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Preamble 
It is becoming more apparent each day that despite a strong 
national commitment to excellence in health care, the re- 
sources and personnel are finite. It is therefore appropriate 
that the medical profession examine the impact of devebping 
technology and new therapeutic modalities on the practice of 
cardiology. Such analysis, carefully conducted, could poten- 
tially affect the cost of medical care without diminishing the 
effectiveness of that care. 
To this end, the American College of Cardiology and the 
American Heart Association in 1980 established a Task Force 
on Assessment of Diagnostic and Therapeutic Cardiovascular 
Procedures with the following charge: 
These guidelines wiere approved by tbr American College of Cardiology 
Board of Trustees and the American Heart Association Steering Committee in 
October 1994. 
Address for reorints: Educational Services, American College of Cardiology, 
9111 Old Gcorgctown Road. Belhesda, Ma@md 20814. 
The Task Force of the American College of Cardiology and the 
American Heart Association shall develop guidelines rela- 
tive to the role of new therapeutic approaches and of 
specific noninvasive and invasive procedures in the diagno- 
sis and management of cardiovascular disease. 
The Task Force shdil address, when appropriate, the contrihu- 
tion. uniqueness, sensitivity, specificity, indications, contra- 
indications and cost-effectiveness of such diagnostic proce- 
dtires and therapeutic modalities. 
The Task Force shall emphasize the role and va!ues of the 
developed guidelines as an educational resource. 
The Task Force shall include a Chairman and six members. 
three representatives from the American Heart Association 
and three representatives from the American College of 
Cardiology. The Task Force may select ad hoc members as 
needed upon the approval of the Presidents of both orga- 
nizations. Recommendations of the Task Force are for- 
warded to the President of each organization. 
The members of the Task Force are Melvin D. Cheitlin, 
MD, Arthur Garson, Jr., MD, MPH, Richard P. Lewis, MD. 
Robert A. O’Rourke, MD, Thomas J. Ryan, MD, Robert C. 
07.15-1047i95iS9.50 
0735-1UY7(94)00522-R 
522 ACCIAHA TASK FORCE 
GUIDELINES FOR CLINICAL CARDIAC RADIONUCLIDE IMAGING 
JACC Vol. 25, No. 2 
February lYY5:521-47 
Schlant, MD, William L. Winters, Jr., MD and James L. 3. the cost and accuracy sf the technique as compared with 
Ritchie, MD, Chairman. o?er diagnostic procedures; and 
The Committee on Cardiac Radionuclide Imaging was 
chaired by James L. Rhchie, MD and included the following 
members: Timothy M. Bateman, MD, Robert 0. Bonow, MD, 
Michael H. Crawford, MD, Raymond J. Gibbons, MD, 
Robert J. Hall, MD, Robert A. O’Rourke, MD. .IlfrcJ F. 
Parisi, MD and Mdrio S. Verani, MD. 
This document was reviewed by the officers and other 
responsible individuals of the American College of Cardiology 
and American Heart Association and received final approval in 
October 1994. It is being published simultaneously in Ci~ulu- 
tion and Journal of the American College of Cardiology. The 
document also was reviewed and endorsed by the American 
Society of Nuclear Cardiology and will be published in the 
March/April issue of the Journal of Nuclear Ctirdiolofl. 
4. the effect of positive or negative results on subsequent 
clinical decision making. 
The formhit of the present report includes a brief descrip- 
tion of nuclear cardiologic techniques, followed by a discussion 
of its usefulness in specific cardiovascular diseases. Utility is 
considered for 1) diagnosis, 2) severity of disease/risk assess- 
ment/prognosis, and 3) assessment of therapy. The tables that 
appear in each section summarize the recommendations for 
that particular disease entity. 
Introduction 
The American College of Cardiology/American Heart Asso- 
ciation Task Force on Assessment of Cardiovascular Procedures 
was formed to make recommendations regarding the appropriate 
utilization of technology in the diagnosis and treatment of pa- 
tients with cardiovascular disease. One such important technology 
is cardiac radionuclide imaging (nuclear cardiology). 
The current committee was given the task of reviewing and 
revising the Guidelines for Clinical Use of Cardiac Radionu- 
elide Imaging, December 1986 (1). Since that repori, many 
changes have taken place and are considered in the present 
report, including the development of pharmacologic stress 
testing, the development of new classes of isotopes (techne- 
tium- atid rubidium-based perfusion agents) and refinements 
in single-photon emission comppted tomography (SPECT) 
and positron emission tomography (PET). 
Similar to the previous report, the usefuiness of cardiovas- 
cular imaging techniques in specitic disease states is indicated 
in ihe present report by means of the following classification: 
class i = usually appropriate and considered useful; 
&ss II = acceptable but usefulnesT less well established; 
class Ha = weight of evidence in favor of usefulness; 
class ZZb = can be helpful but not well established by evidence: 
c/ass III = generally not appropriate. 
Techniques considered investigational are ilot further classi- 
fied. 
The Committee reviewed and compi!ed all pertinent pub- 
lished reports (by computerized and hand search, excluding 
abstracts), and recommendations made are derived from these 
reports. When no or few data existed, this is identified in the 
text, and recommendations are based on committee consensus. 
A complete list of the multiple publications on cardiac imaging 
is beyond the scope of this communication, and only selected 
references are included. The Committee membership con- 
sisted of acknowledged experts in radionuclide testing, as well 
as general cardiolclgists and cardiologists with expertise in 
other imaging modalities; both the academic and private 
practice sectors were represented. This document will be 
reviewed 2 years after the date of publication and yearly 
thereafter by the Task Force to determine whether a revision 
is needed. The guidelines will be considered current, unless the 
Task Force publishes revisions or a withdrawal. 
This report does not include a discussion of digital subtrac- 
tion angiography, high speed (tine) computed tomography or 
nuclear magnetic resonance imaging, which are not radionu- 
elide based per se but were included in the 1986 guidelines. 
This guideline applies to adults; indications for radionuclide 
testing in children are not included. 
Description of Specific Procedures 
In considering the use of a specific cardiovascular radionu- 
elide technique in individual patients, the following factors are 
important: 
1. the quality of the available laboratory and equipment used 
for performing the study and the quality, expertise and 
experience of the professional and technical staff perform- 
ing and interpreting the study; 
2. the sensitivity, specificity and accuracy of the technique; 
Most current nuclear cardiology applications utilize a 
gamma camera of either 1) the single-crystal type, or 2) the 
multicrystal type. The single-crystal gamma camera (Anger 
camera) is the most widely available system. It is technically 
adequate for generating most of the clinically important nu- 
clear cardiology information, that is, equilibrium (gated) blood 
pool angiographf, myocardial perfusion imaging and myocar- 
dial infarct-a>+ imaging. The SPECT images are tomographic 
reconstructions derived from either a single- or multiple-head 
gamma camera tl,.at rotates around the patient. Tomographic 
imaging, by displazling data in the format of slices with discrete 
tiiickness, allows better separation of myocardial and other 
nonmyocardial strltctures and individual coronary artery beds 
and is inherently iplantitative. A standardized nomenclature 
for tomographic views (short axis, vertical long axis and 
horizontal long ax&) and displays has been developed for both 
SPECT and PET (;I). The multicrystal camera has a somewhat 
lower resolution bit is generally a more sensitive device; thus, 
it is best used for “first-pass” radiotracer studies. 
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The positron camera or PET scanner consists of multiple 
rings of stationary detectors that encircle the thorax, detect the 
high energy photons (511 keV) that are released from 
positron-emitting tracers and produce a series of multiple 
tomographic images encompassing the heart. Positron cmis- 
sion tomographic tracers have been developed for the evalua- 
tion of numerous physiologic processes, including regional 
myocardial blood flow, metabolic processes, oxygen consump- 
tion, receptor activity and membrane function. Improved 
quantitation of these processes is possible with PET. Positron 
emission tomographic scanners are more costly and less widely 
available than standard Anger cameras or SPECT systems. 
Gamma Camera Imaging 
(Single-Photon Approaches) 
Radionuclide angiography. “First-pass” approach (rest, 
stress). First-pass radionuclide angiography utilizes rapidly 
acquired image frames to observe a bolus of technetium-99m 
or another suitable radionuclide as it moves through the 
venous system into the ;&ht e’rium, right ventricle, pulmonary 
artery, lungs, left atrium, left ventricle and aorta. Because the 
sampling rate is short relative to the RR interval, it is possible 
to sample continuously several cardiac cycles as the bolus 
passes through the right and then the left ventricle. By 
determining the change in radioactivity over time (i.e., by 
generating :ime-activity curves), it is possible to derive ejection 
fraction measurements from both the right and the left ventri- 
cles. It is also possible to measure ventricular and pulmonary 
blood volumes and to assess regional ventricular wall motion. 
The first-pass approach is uniquely well suited for shunt 
detection and quantitation and evaluation of right ventricular 
function because the right and left ventricles can be temporally 
isolated. Left-to-right shunts can be quantitated by application 
of a mathematical approach to a region of interest placed over 
the lting. The first-pass approach ran be applied to patients 
both at rest and during exercise stress. 
Gated equilibrium bbod pool radionuclide angiography (rest, 
stress}. Equilibrium or gated blood pool radionuclide angiog- 
raphy most commonly utilizes technetium-99m (Tc-99m) per- 
technetate bound to red blood cells. Accordingly, technetium 
remains within the blood pool, and serial imaging studies to 
assess function can be acquired over several hours. Acquisition 
of the images is synchronized with the electrocardiographic 
(ECG) QRS complex. Every cardiac cycle is divided tempo- 
rally into numerous frames, and all corresponding frames from 
all the cycles within a given RR interval range are added 
together for an acquisition time ranging from 2 to 10 min. The 
resultant study provides composite images of all cardiac cycles 
during this time period. The equilibrium blood pool approach 
generates reliable left and right ventricular ejection fraction 
values and a means for assessing regional wall motion. It can 
be applied both at rest and during exercise stress or pharma- 
cologic stress. In addition, it can be used to measure ventric- 
ular volumes, changes in pulmonary blood volumes with stress 
and valvular regurgitant fractions. Equilibrium studies can be 
acquired by both planar and SPECT approaches. 
Myocardial perfbsion imaging. Thallium-201. A unique 
feature of nuclear cardiology is the ability to image regional 
myocardial blood flow distribution. Thallium-201 is very effi- 
ciently extracted by viable myocardial cells. After intravenous 
administration, thallium distributes in proportion to regional 
blood flow. Images of the heart shortly after thallium >:min- 
istration show deficits in regions where blood flow is relatively 
reduced and in zones of nonviable myocardium (e.g., previous 
myocardial infarction). Over time, “redistribution” of isotope 
generally occurs in previously ischemic zones, that is, defects 
related to ischemic myocardium normalize or “fill in.” Defects 
related to infarcted or scarred myocardium typically do not 
“redistribute” over time and remain fixed. However, imaging 
at 24 h or after reinjection of thallium-201 may show viable but 
hypoperfused segments not otherwise identified by a standard 
redistribution study performed at 3 to 4 h after isotope 
injection. Assessment of lung thallium-201 activity on the 
initial unprocessed anterior view image provides a means to 
assess exercise-induced increases in pulmonary venous pres- 
sures. Thallium studies can be performed at rest, with exercise 
or dobutamine stress or after the myocardial hyperemia in- 
duced by intravenous administration of dipyridamole or aden- 
osine. Myocardial perfusion imaging is most commonly used in 
conjunction with exercise stress, with thallium-201 adminis- 
tered through an indwelling intravenous line at peak exercise. 
The patient then exercises for an additional 30 to 60 s, and images 
are generally acquired immediately after and again 3 to 4 h after 
thallium administration. In patients with stable angina who are 
unable to exercise, pharmacologic “stress” (i.e., dobutamine, 
adenosine or dipyridamole) has been used to induce myocardial 
hyperemia, with subsequent regional in- homogeneities in the 
perfusion pattern rela!ed to coronary stenoses. Finally, in patients 
with unstable angina or acute myocardial infarction, a perfusion 
stud: w be performed at rest. As with exercise, serial imaging 
can be performed after pharmacologic or rest thallium adminis- 
tration and demonstrate redistribution in regions of rest &hernia 
or underperfused but viable myocardium. 
Technetium-99m-based agents. Recently, technetium99m 
(Tc-99m) sestamibi and Tc-99m teboroxime were introdu<cd for 
myocardial perfusicn imaging. Other technetium-based dgents, 
such as tetrofosmin and furifosmin, may be introduced in the near 
future and used in a similar manner. The shorter half-life of 
technetium99m (6 h) compared with thallium-201 (73 h) allows 
administration of a larger dose, with resulting improved count 
statistics. The more favorable imaging characteristics of techne- 
tium%n (higher emission energy, less scattered radiation) are 
additional benefits cf using this agent. There is a good correlation 
between thallium-201 or sestamibi uptake and myocardial blood 
flow when the latter is normal, decreased or moderateiy increased 
(up to two times the baseline values). The uptake underestimates 
flow when the latter is increased >2.0 to 2.5 times the baseline 
values. Because sestamibi only undergoes a small amount of 
washout after initial myocardial uptake, the distinction between 
transient, stress-induced perfusion defects and fixed perfusian 
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defects requires administration of two separate injections, one 
during stress and one at rest. 
Technetium-99m teboroxime is another myocardial perfu- 
sion agent available in the United States. Because it undergoes 
rapid washout after initial accumulation in the myocardium, 
imaging with teboroxime is technically more difficult and must 
be completed within 2 to 8 min from the time of injection. This 
requirement is especially difficult to meet with single-head 
SFECT systems. Imaging may be optimized by using systems 
with two or three detectors. Fast, dynamic acauisition by 
planar ima@g has also been used to minimize the problem of 
rapid washout?Teboroxime undergoes prominent liver uptake, 
which may render interpretation of the inferior wall of the 
heart difficult. Imaging with the patient sitting upright has been 
proposed to overcome the liver activity by displacing it in- 
feriorly. 
Myocardial infarct-avid imaging. Another unique aspect 
of radionuclide imaging involves the administration of T-99m 
(stannous) pyrophosphate or labeled antibody to cardiac 
myosin* for imaging myocardial infarction. These agents are 
localized in zones of recently infarcted myocardium. The most 
intense visualization of infarcted regions usually occurs 48 to 
72 h after infarction for Tc-99m pyrophosphate. 
Positron Emission Tomography 
Instrumentation. Positron emission tomographic tracers si- 
multaneously emit two high energy photons in opposite direc- 
tions. The ability to detect these two simultaneously generated 
photons (bxlgoincidence detection) allows the PET scanner to 
identify and localize true events and reject single (i.e., un- 
paired) photons as random, scattered photons. Such high 
energy photons and coincidence detection allow improved 
spatial resolution compared to SPECT. Coincidence detection 
provides a means of correcting for tissue photon attenuation, a 
capability not yet fully demonstrated with SPECT. Such atten- 
uation correction results in improved measurement of regional 
tracer activity compared with SPECT methods and permits 
true quantification of this activity, which can be translated into 
quantification of physiologic and metabolic processes. Such 
quantitation is facilitated further by the high temporal resolu- 
tion capability not available with SPECT. 
Positron-emitting tracers, A number of tracers have been 
developed for clinical PET studies. These include oxygen-15 
(half-life 2 min), mtrogen-13 (half-life 10 min), carbon-11 (half- 
life 20 min) and fluorine-18 (half-life 110 min), which may be 
coupled to a number of physiologically active molecules. These 
tracers require a local or on-site cyclotron for production, except 
for fuorine-18, which can be shipped for same-day use. Rubidi- 
um-82 (half-life 75 s) does not require a cyclotron and may be 
delivered directiy to the patient from an on-site generator. The 
most frequently used agents to assess myocardial perfusion with 
PET are rubidium-82, nitrogen-13 (N-13) ammonia and oxy- 
*Not Food and Drug Administration (FDA) approved. 
gen-15 (O-15) water. Carbon-11 (C-lI)--labeled fatty acids and 
fluorine-18 (F-18) fluorodeoxyglucose are cummon metabolic 
tracers, and C-11 acetate is used as an agent to assess oxidative 
metabolism and oxygen. consumption. 
Clinical applications. There are two specific clinical appli- 
cations of PET that have been proposed for the evaluation of 
patients v;ith coronary artery disease. Tht first is the noninva- 
sive detection of coronary artery disease and estimation of the 
severity of the disease. This is performed using a PET perfu- 
sion agent at rest and during pharmacologic vasodilation. The 
short half-lives of these agents permit rapid sequential exam- 
inations, such as rest-dipyridamole studies, within a short time 
frame (1 to 2 h). A unique application of PET is the noninva- 
sive calculation of absolute regional myoaa’rdial blood flow or 
absolute rnyocardial blood flow reserve in humans using O-15 
water or N-13 ammonia. However, most centers rely on the 
qualitative or semiquantitative interpretation of rubidi?rm-82 
or N-13 ammonia images for both the diagnosis of coronary 
artery disease and the estimation of its severity. The second 
clinical application of PET is the assessment of myocardial 
viability in patients with coronary artery disease and left 
ventricular dysfunction. The most common approach is to 
determine whether metabolic activity is preserved in regions 
with reduced perfusion, using F-18 fluorodeoxyglucose as a 
marker of glucose utilization and thus tissue viability. 
Clinical Uses of Radionuclide Imaging 
Acute bfyocardial Infarcticn 
Diagnosis. The clinical use of radiocuclide imaging for the 
diagnosis of acute myocardial infarction should be restricted to 
special imited situations where the triad of history, ECG changes 
and laboratory measurements is unavailable or less reliable. 
In patients who present late (-?4 h and ~7 days) without 
diagnostic ECG changes and in patients early after coronary 
rtery bypass surgery, myocardial infarct-avid scintigraphy 
u,ing Tc-99m pyrophosphate has moderate sensitivity and 
specificity in the diagnosis of acute myocardial infarction (3,4). 
Localized uptake of pyrophosphate usually indicates myocar 
dial necrosis, although false-positive results can occur in the 
presence of intracardiac calcification, ventri.ular aneurysm 
and previous myocardial infarction. If the test is performed 
~24 h or >7 days after the onset of infarction, false negative 
results are frequent. A possible exception is the administration 
of pyrophosphate within 2 to 3 h after successful thrombolytic 
therapy (5). False-negative results may also occur after small 
infarctions whet. planar imaging is used (6); however, SPECT 
imaging allows the detection of a number of the smaller 
infarcts that may be missed by planar imaging. Pyrophosphate 
scintigraphy usually permits localization of the area of myo- 
cardial necrosis. More recently, infarct-avid scintigraphy with 
antimyosin antibody has been described as an alternative to 
pyrophosphate scintigraphy (7,8), but antimyosin antibody 
imaging remains investigational in the IJnited States at this 
time. Sensitivity comparisons between pyrophosphate and an- 
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timyosin antibody imaging have generally provided similar compensatory hyperkinesia is highly associated with subse- 
results. quent patient outcome (20-22). 
In selected patients with right ventricuiar infarction, radio- 
nuclide imaging may also have a role in diagnosis. Right 
ventricular infarction can often be diagnosed at the beds&. 
When these findings are not definitive, pulmunary artery 
catheter placement or right ventricular imaging may be indi- 
cated. In these circumstances, radionuciide angiography may 
support the diagnosis of right ventricular infarction by demon- 
strating a reduced right ventricular ejection fraction and right 
ventricular asynergy (9). In patients in whom right ventricular 
infarction is suspected to have occurred >.?4 h previously, the 
localization of myocardial necrosis to the -ight ventricle by 
pyrophosphate scintigraphy may also be useful. 
Myocardial perfusion imaging with thallium-201 and Tc- 
99m sestamibi can also be used to assess infarct size (22-24). 
IMost recently, Tc-99m sestamibi has been utilized with tomo- 
graphic imaging for this purpose. Measurements of infarct size 
with Tc-99m sestamibi have been correlated closely with other 
measurements of infarct size, including ejection fraction (13) 
regional wall motion score (l3), creatine kinase release (17) 
and thallium-201 defect size (24). However, no long-term 
studies are available to demonstrate an association with patient 
outcome. 
Localized perfusion defects occur in a high percentage of 
patients with acute left ventricular infarction that is associated 
with coronary occlusion (10). However, such perfusion defects 
do not distinguish between acute ischemia, acute infarction or 
previous infarction. Serial changes on follow-up perfusion 
images with either thallium-201 or Tc-99m sestamibi suggest 
an acute process but still do not distinguish between ischemia 
or infarction. 
Radionuclide techniques are useful for assessing the pres- 
ence and extent of stress-induced ischemia. In patients who did 
not receive repetfusion therapy, both exercise radionuclide an- 
giography (19) and exercise or pharmacologic stress thallium-201 
perfusion imaging (25) have been carefully studied. Both are 
superior to the exercise ECG in the identification of patients who 
are likely to have subsequent cardiac events. 
Severity of disease/risk assessment/prognosis. The clinical 
severity of acute infarction is primarily a function of infarct 
size. The principal determinant of infarct size is the amount of 
myocardium at risk for infarction at the time of coronary 
occlusion, even if successful reperfusion occurs. Animal and 
clinical stadies have documented the variability of myocardium 
at risk for a given coronary occlusion (1 l-13), which presum- 
ably reflects both the variation in the actual territcries supplied 
by the native coronary arteries and the effect of coronary artery 
collateral vessels. 
Technetium-99m sestamibi is uniquely suited to the accu- 
rate measurement of myocardium at risk in clinical infarction. 
Because there is minimal redistribution of the radiopharma- 
ceutical over time, imaging can be delayed for several hours 
after injection and strll provide accurate information about 
myocardial perfusion at the time of injection. The validity and 
feasibility of this approach has been well established in animal 
and clinicai studies (14-17). 
As mentioned previously, myocardium at risk is a major 
determinant of final infarct size. However, final infarct size 
may be considerably smaller than the initial myocardium at 
risk, reflecting the effects of reperfusion therapy, spontaneous 
reperfusion and collateral blood flow (11). Clinical data have 
demonstrated the importance of final infarct size as a major 
determinant of subsequent patient survival. Radionuclide tech- 
niques are clearly useful for this purpose. In patients who have 
not received reperfusion therapy measurement of rest ejection 
fraction and end-systolic volume index before hospital da- 
charge by equilibrium-gated radionuclide angiography is highly 
associated with subsequent patient outcome (l&19). In pa- 
tients who have recetved reperfusion therapy, the post-. 
discharge rest ejection fraction by equilibrium radionuc!ide 
angiogrzphy after the resolution of myocdrdial stunning and 
There are far fewer data available regarding risk siratifica- 
tion using predischarge exercise testing 111 p&ents who have 
received thrombolytic therapy. It is now recocnizcd that pa- 
tients enrolled in clinical trials of thrombolyti- therapy are less 
likely to have severe three-vessel coronary artery disease (26). 
In addition, coronary angrography is often performed during 
the hospital period in patients with recurrent chest pain, 
thereby identifying many patients with severe disease who 
merit revascularization (27). Patients who receive thrombolytic 
therapy have a significantly smaller infarct size As a conse- 
quence of all of these factors, the patient Iopulation that 
underg:es predischarge exercise testing in clinical trials of 
thrombolytic therapy is far different from less se!ected, histor- 
ical populations (28). Preliminary data have suggested that the 
long-term event rates in such patients are far lower (29). Many 
studies are in progrtJs that will reassess the validity of risk 
stratification using radionuclide techniques in patients wha 
have received thrombolytic therapy. However, prospective 
natural history studies are dithcult to undertake because 
clinicians now mtehrvien;; with angiogr aphy and revasculariza- 
tion in patients with hn ischenuc response on predischarge 
stress perfr;;ion imaging. 
In patients v#ho kre unable to exercise after myocardial 
infarction due to orthopedic or other physical limitations, 
pharmacolr,gtc stress perfusion imaging is a useful alternative. 
Pfrarma;ologic stress also appears useful in patients with left 
bundle branch block in whom exercise perfusion images are 
dQicu!t :o interpret (30,31). Dipyridamole (32) and adenosine 
thallium-201 studies (33) are clearlv useful in the identification 
ai patients who are at high risk for subsequent cardiac events. 
Such testing may be performed as early as 48 to 72 h after 
admission to t’y to identify high risk patients (34,35), although 
the safety of this approach remains to be established. Myocar- 
dial viability is another important prognostic issue after myo- 
cardial infarction. 
Echocardiography is most commonly used when mechani- 
cal complications associated with acute myocardial infarction 
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Table 1. Uses of Radionuclide Testing in Diagnosis of Acute 
Myocardial Infarction 
Indication 
1. Right ventricular infarction 
2, Infarction not diagnosed by standard 
means-early presentation with 
successful rep&&ion 















4. Routine diagnosis Any technique 111 
Class 1 = usually appropriate and considered useful; class II = acceptable 
but usefulness less well established; class IIa = weight of evidence in favor of 
usefl~lness; class IIb = can be helpful but not well established by evidence; class 
III = generally appropriate; RNA = radionuclide angiography: Tc = techne- 
tium. 
are suspected. Radionuclide techniques may be a useful alter- 
native to assess mechanical complications when echocardiog- 
raphy is not available or definitive. The diagnosis of left 
ventricular aneurysm and pseudoaneurysm are feasible with 
radionuclide angiography. First-pass radionuclide angiography 
can be used to detect and quantitate shunting in the assess- 
ment of infarct-related ventricuiar septal defect. 
Assessment of therapy. The assessment of the efficacy of 
acute reperfusion therapy with either thrombolysis or percu- 
taneous transluminal cornnary angioplasty is an important 
clinical issue in an increasing number of patients. There are 
two separate but clearly interrelated issues-the determination 
of early reperfusion after acute therapy and the measurement 
of myocardial salvage. 
Serial tomographic imaging with Tc-99m sestamibi haq been 
used at 18 to 48 h after therapy to assess coronary artery 
patency (36). In this time frame, it will clearly identify patients 
who have both coronary artery patency and cariy evidence of 
myocardial salvage, but it will be unable to distinguish patients 
with persistent occlusion from patients with patent arteries 
without early evidence of myocardial salvage. Technetium-99m 
sestamibi imaging has yet to be tested earlier after reperfusion 
therapy (perhaps 4 to 6 h) when additional rtvascularization 
might still be feasible. Teboroxime perfusion imaging is also 
potentially promising for the assessment of early coronary 
artery patency (37). 
Serial imaging with Tc-99m sestamibi can be used to assess 
myocardial salvage (38). Because this radiopharmaceutical 
measures hnal infarct size, it can determine myocardial sal- 
vage. Tables 1 and 2 summarize and class@ the indications for 
radionuclide testing in acute myocardial infarction. 
Unstable Angina 
Diagnosis. The clinical use of radionuclide imaging for the 
diagnosis of urstable angina should be restricted to limited 
situations where the combination of history and ECG changes 
are unavailable or less reliable. In these circumstances, radio- 
nuclide techniques may be useful adjuncts for the diagnosis of 
unstable angina. Their clinical applicability is primarily an issue 
of logistics. Planar thallium imaging is useful for the detection 
of reversible, segmental myocardial perfusion defects (39,40). 
Redistribution on such images provides an indication of re- 
gional myocardial viability that differentiates ischemia at rest 
from previous infarction. However, the detection of redistri- 
bution requires prompt initial imaging, generally within 
30 min, before the myocardial distribution of thallium-201 has 
changed substantially. This limits its usefulness in acutely ill 
patients. 
Technetium-99m sestamibi tomography is useful for the 
detection of rest perfusion abnormalities (41). Because of the 
lack of clinically significant redistribution of this agent; imaging 
can be delayed for 1 to 6 h and still allow dciermination of 
myocardial perfusion at the time of administration. Logistic 
barriers to the use of this agent are 1) the time required for 
preparation, which is -5 to 20 min, and 2) the fact that an hour 
delay is required before imaging to allow liver clearance (42). 
Thus, chest pain must persist long enough to permit the 
preparation and administration of the agent. 
Severity of disease/risk assessment/prognosis. In the acute 
setting, the clinical use of radionuclide imaging to assess the 
‘fable 2. Uses of Radionuclide Testing in Risk Assessment, Progilosis and Assessment of Therapy 
After Acute Myocardial Infarction - 
Indication Test Class 
I. Rest RV/LV function 
2. Presenceiextert of stress-induced ischemia 
3. Detection of viable myocardium 
4. Detection of infarct size 
5. Acute measurement of myocardium at risk 
6. Measurement of rnyocardial salvage 
-- 
Rest RNA 
Stress myocardial perfusion imaging 
Stress RNA 
See TaSle 4: Uses of Radionuclide 
Testing in Diagnosis of Chronic 
Ischemic Heart Disease 
Rest myocardial perfusion imaging 
Rest Tc-99m sestamibi perfusion 
imaging 








LV(RV) = left (right) ventricular; other abbreviations as in Table 1. 
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Table 3, Uses of Radionuclide Testing in Diagnosis. Prognosis and Assessment of Therapy in Patients 
With Unstable Angina 
Indication 
1. Identification of ischemia in tilt distribution 
of the “culprit” lesion or in remote areas 
Test 
Stress myocardial perfusion imaging 
Class 
I 
2. Identification of the severity/extent of disease 
in patients with ongoing ischemia 
Rest myocardial perfusion imaging Ila 
3. Identification of the severity/extent of disease 
in patients whose angina is satisfactorily 
stabilized with medical therapy 
Stress myocardiai perfusion imaging IIa 
4. Diagnosis of myocardial ischemia in patients 
where the combination of history and ECG 
changes are unreliable 
5. Measurement of baseline LV function 




ECG = electrocardiographic; other abbreviations as in Tables I and 2. 
severity of disease and patient risk should be restricted to those 
situations where history and ECG assessment are not defini- 
tive. Myocardial perfusion imaging can provide accurate infor- 
mation about the extent and location of the decrease in blood 
flow (39,41). This information is generally more precise than 
that provided by the ECG. It may be helpful in patient 
management, particularly with respect to identification of the 
“culprit” angiographic lesion when revascularization with an- 
gioplasty or operation appears to be necessary. Although such 
information could conceivably be obtained with either thalli- 
um-201 or Tc-99m sestamibi perfusion imaging, the latter 
radionuclide is generally preferable because imaging of the 
acutely ill patient can be delayed for a period of several hours 
if necessary. 
Radionuclide techniques are potentially useful with respect 
to two specific issues concerning the prognosis in patients with 
unstable angina-assessment of myocardial viability and pre- 
diction of future cardiac events in patients whose angina is 
successfully stabilized with medical therapy. 
Some p&=nts with unstable angina will have normal re- 
gional and mecha&::al function between episodes of chest 
pain. In such patients, the myocardial segments that develop 
regional dysfunction during pain can be presumed to be viable. 
However, many patients will continue to have global and 
regional dysfunction between episodes of chest pain, which 
may represent ongoing subclinical ischemia or myocardial 
stunning. In patients with mechanical dpfunction, myocardial 
perfusion imaging with thallium-201 is valuab!e to distinguish 
myocardial stunning or ongoing ischemia from previous myo- 
cardial infarction, or both. Technetium-99m sestamibi is also 
potentially useful in this regard. 
In patients with uns?able angina that is satisfactorily stabi- 
lized with medical therapy, myocardial perfusion imaging can 
help determine future cardiac risk. The size and number of the 
perfusion defects are the best predictors of the extent of 
underlying coronary artery disease. The presence and extent of 
thallium-201 redistribution on stress testing (after stabiliza- 
tion) are predictive of subsequent cardiac death and nonfatal 
myocardial infarction (43,44), Myocardial perfusion imaging is 
therefore one option for the noninvasive risk stratification of 
patients whose angina is stabilized with medical therapy (45). 
Assessment of therapy. Radionuclide angiography sari as- 
sess improved left ventricular function in patients who have 
undergone revascularizatioa and have evidence of dysfunction 
between episodes of unstable angina. Myocardial perfusion 
imaging can document the improvement in rest perfusion to 
areas with previous rest ischemia. Both exercise and pharma- 
cologic stress with perfusion imaging are useful for assessing 
the completeness of revascularization and for determining the 
functional significance of any unrevascularized lesions. The 
utilization of these techniques in patients with previous unsta- 
ble anginh who have undergone revascularization is essentially 
similar to their application in patients with chronic ischemic 
heart disease. Table 3 summarizes the indications for radionu- 
elide testing in unstable angina. 
Chronic Isclzernic Heart Disease 
Radionuclide imaging has played a pivotal role in the 
diagnosis and risk stratification of patients with coronary artery 
disease. The largest accumulated experience in myocardial 
perfusion imaging has been with the tracer thallium-201, but 
the available evidence suggests that the newer tracer Tc-99m 
sestamibi yields similar diagnostic accuracy (46-54). Thus, for 
the most part, thallium-201 or Tc-99m sestamibi can be used 
interchangeably, with similar diagnostic accuracy in coronary 
artery disease. Myocardial perfusion imaging may use either 
planar or tomographic (SPECT) techniques, Thallium-201 
SPECT is generally more accurate than planar imaging for 
diagnosing coronary artery disease, localizing hypoperfused 
vascular territories, identifying left anterior descending and 
left circumflex coronary artery stenoses (55) and correctly 
predicting the presence of multivessel coronary artery disease 
(56). Thus, SPECT is generally preferable to planar imaging, 
although the latter remains useful if the more expensive and 
complex SPECT gamma cameras are not available, or if the 
patient cannot tolerate lying on the SPECT table because of 
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musculoskeletal reasons, or for bedside imaging in an intensive 
care unit. 
Diagnostic accuracy of myocardial perfusion imaging in 
chronic coronary artery disease. ThaXum-201 planar scinfig- 
rep@. The utility of thallium-201 planar scintigraphy in the 
diagnosis of coronary artery disease was extensively doctr- 
mented in the late 1970s and early 1980s. The average values of 
sensitivity and specificity are 83% and 8P%, respectively, by 
visual analysis (57-60). The less than perfect sensitivity and 
specificity may in part be explained by the fact that visually 
estimated angiographic severity of coronary stenoses does not 
closely correlate with functional severity as assessed by coro- 
nary flow reserve after maximal pharmacologic coronary vaso- 
dilation (61). 
Quantitative techniques have been used in association with 
planar thallium-201 perfusion imaging. These techniques are 
based on the distribution of thallium-201 activity over the 
myocardium assessed by horizontal (62) or circumferential 
(63-65) profiles. Myocardial segments with abnormal thalli- 
um-201 uptake and washout are identified versus either normal 
segments in the same image (62) or relative to the vaiues of a 
normal cohort (64-66). 
Qtiantification of planar thallium-201 images may improve 
the test’s sensitivity, especially in patients with .,inglt:-vessel 
disease (60,65-69). The overall reported sensitivity for quan- 
titative planar thallium scintigraphy is 90% (611). However, 
quantification techniques may at times result in lower specific- 
ity, particularly when they rely on isolated analysis of thallium- 
201 washout, which can be affected by such factors as intensity 
of exercise, peak heart rate achieved and diet consumed by the 
patient between the stress and redistribution images. Overail 
specificity of quantitative thallium scintigraphy is 80%. 
Thallium-201 Sl’lXF scinfigraphy. Qualitative analysis of 
SPECT has resulted in a higher frequency of detection of 
coronary artery disease relative to planar scintigraphy (55). 
The average sensitivity and specificity of qualitative exercise 
thallium-201 SPECT are 89% and 76%, respectively (67,6!?,70). 
Sing&photon emission computed tomography has afforded 
diagnostic improvement over planar imaging for more precise 
localization of the vascular terri?aries involved, particularly the 
identification of left circumflex coronary artery stenoses and 
prediction of multivessel coronary arterv disease (67,69,70). 
Quantitative analysis of thailium-201 SPECT has further en- 
hanced its accuracy. This has been achieved by generating 
perfusion maps of the three-dimensional myocardial thallii:m- 
201 Zctivity on the basis of circumferential profiles of individ- 
ual myocardial slices, which are then displayed on a “polar 
map” or “bull’s-eye” plot. Computer coding of abnormally 
perfused myocardium, relative to a composite map from 
normal subjects, can then be obtained and expressed as a 
percentage of left ventricular volume (70-77). A recent review 
of studies using quantitative analysis of exercise thai:ism-2.91 
SPECT has shown an overall sensitivity of 90% and specificity 
of 70% (70). The lower than expected specificity in tbesr 
recent series has been ascribed to a “posttest referral bias” that 
postulates that patients with abnormal SPECT study results 
are preferentially referred for cardiac catheterization. This 
selection process would curtail the nurnhev of “true negative” 
results in the studies because most subjects with normal 
SPEC? results would not undergo coronary angiography. 
The end result of such a selection bias wculd be to decrease the 
specificity of the test while at the same time increasing the 
test’s sensitivity. In an attempt to circumvent this “posttest 
referral bias,” some investigators have proposed a ‘-normalcy 
rate” as a surrogate for specificity. The normalcy rate is the 
fraction of negative studies in a cohort caf “clinically normal” 
subjects, meaning subjects with a very low likelihood of having 
coronary artery disease on the basis of history, negative 
physical findings and normal exercise ECG test results but who 
have not had heart catheterization. The normalcy rate by 
quantitative thallium-201 SPECT averages 89% (70). 
Although patient selection undoubtedly plays a role in 
decreasing the observed SPECT specificity, it is likely that 
other factors, such as photon attenuation and artifacts created 
by tht: tomographic reconstruction process, are also important. 
Clearly, SPECT requires more rigorous quality control for 
image acquisition and processing than planar imaying. 
Technetium-99m perfusion tracers. Most of the studies com- 
paring Tc-99m sestamibi with thallium-201 perfusion imaging 
or coronary angiography have used a 2-day sestamibi protocol. 
These studies have been recently summarized (53,54). By 
quantitative analysis of planar imaging, the average sensitivity 
and specificity were similar to those of thallium-201 scintigra- 
phy. By quantitative analysis of SPECT, the corresponding 
values are similar to those of quantitative thallium-201 SPECT. 
On average, SPECT imaging yields better detection of individ- 
uzl coronary stenoses than planar imaging with Tc-99m sesta- 
mibi (54,78). Reports of several small series have documented 
the diagnostic sensitivity and specificity of exercise Tc-99m 
teboroxime imaging, and they appear to be comparable to 
those of exercise thallium-201 imaging (79-83). 
Positron emission fomogruphy. A number of studies, involv- 
ing a total of several hundred patients, indicate that perfusion 
imaging with PET using dipyrida&e and either rubidium-82 
or N-13 ammonia demonstrates abnormal coronary perfusion 
patterns in the majority of patients with coronary artery 
disease. This experience indicates that PET may be a sensitive 
and specific clinical means to diagnose coronary artery disease 
(84-92). Sensitivities with either tracer range from 87% to 
97%, with specificities from 78% to 100%. At the present time, 
rubidium-82 is the only PET perfu:;ion tracer approved by the 
FDA for clinical use; N-l3ammonir. is also used for assess- 
ment of myocardial perfusion, yet is still considered investiga- 
tional by the FDA. The advantage of rubidium-82 is that it is 
obtained from a generator, obviating the need for a cyclotron; 
the disadvantage is the high cost of the generator. 
Positron emission tomographic versus SPECT imaging. Two 
studies, involving a total of 281 patients, in which PET per- 
fusion imaging with rubidium-82 and dipyridamole was com- 
pared directly with thallium SPECT in the same patients, 
demonstrated significantly higher diagnostic accuracy of PET 
for detecting angiographically documented coronary artery 
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disease. The first study (9Ci) compared thallium-201 SPECT to 
rubidiom- PET, using a single dipyridamole-hand grip stress 
(see later) for both imaging agents and showed improved 
diagnostic accuracy with rubidium-82. These results stemmed 
primarily from lower sensitivity in detecting coronary artery 
disease with thallium (76%) compared with rubidium-82 
(95%). Over 75% of the false negative thallium studies that 
were correctly diagnosed during the rubidium-82 studies in- 
volved the inferior and posterior wall, a region known to have 
greater interpretative errors with thallium-201 because of true 
or perceived photon attenuation. In the second study (91), 
similar sensitivities between thallium SPECI’ (using either 
exercise or dipyridamole) and rubidium-82 PET (using 
dipyridamole-hand grip&Fess) were obtained in identifying 
coronary artery disease (90% and 87%, respectively) and 
inditidual coronary artery stenoses (65% and 64%, respec- 
tively). However, PET achieved higher specificity than SPECT, 
both in the diagnosis of patients (82% vs. 57%, respectively) 
and in identifying individual coronary artery stenoses (92% vs. 
84%, respectively). Although each of these studies reported 
promising results with PET versus SPECT imaging, the results 
may have been influenced by patient referral biases and tirning 
of the PET versus SPECT acquisitions and differing stress 
protocols between PET and SPECT. The low sensitivity of 
SPECT in the first study (90) could reflect the later injection of 
thallium several minutes after administration of the same dose 
of dipyridamole that was used for the stress rubidium-82 image 
acquisition and the fact that both dipyridamole and hand grip 
exercise were used for PET, whereas only dipyridamole was 
used for SPECT. The low specificity of SPECI’ in the second 
study (91) may represent a referral bias because patients 
underwent thallium SPECT imaging before being selected for 
coronary arteriography and PET imaging. Larger, more defin- 
itive comparative studies with comparable expertise in both 
PET and SPECT imaging are required to determine the 
relative diagnostic efficacies of the two techniques. 
It is clear that PET would provide valuable diagnostic 
information in certain individuai clinic?! situations. For exam- 
ple, because of the ability to correct for photon attenuation 
with PET, PET would be v&able in patients with equivocal 
thallium result; related tti questions of photon attenuation or 
in patients whose body habitus is likely to raise issues 3f photon 
attenuation. 
However, it is less certain that PET is unequivocally supe- 
rior to SPECT imaging for routine diagnostic purposa, despite 
its potential for improvement in diagnostic accuracy A recent 
report from the American Heart Association (93) red.t:wed the 
available data and did not find PET superior to SPECT in 
diagnostic accuracy. No new comparative studies have ap- 
peared since that report was published. The available data 
indicate that PET provides a diagnostic accuracy for the 
detection of coronary artery disease and for the estimation of 
disease severity that is similar to SPECT imaging. However, 
the number of patieuts studied by PET is relatively small. Also, 
PET is an expensive imaging modality, and whether the greater 
cost of PET is justified by a possible improvement in diagnostic 
accuracy re luires further rigorous study. Thus, until da!a frcrm 
large-scale. definitive studies are published, PIT is considered 
an effective modality for the noninvasive diagnosis of coronary 
artery disc2 se but should be considered for routine diagncstic 
purposes only if the costs of PET are equivalent to or less than 
the costs 01' SPECT imagmg in the same community. 
Special 1 ssues with regard to exercise perfusion imaging for 
diagnosis 3f coronary artery disease. Concomitant use of 
drugs. Me&cations that decrease myocardial oxygen demands, 
such as be:a-adrenergic or calcium channel blocking agents, 
may limit the development of ischemia during the exercise test. 
Beta-bloclezrs tend to attenuate the exercise-induced increase 
in heart rate. Consequently, the sensitivity of the exercise 
perfusion !,tudy for the diagnosis of coronary artery disease 
appears to be lower in patients taking such agents (74,94-97). 
Whenever feasible, use of beta-blockers and long-acting cal- 
cium channel blockers should be tapered and discontinued at 
least 48 h !>efore the exercise lest. Olie study (98) shows that 
nitrates may also decrease the extent of perfusion defects or 
even conve t t abnormal exercise scan results to normai results. 
Therefore, when feasible, long-acting nitrates should be dis- 
continued at least 12 h before the test, although sublingual 
nitroglycerin may be given as needed up to 2 h before the test. 
Nonetheless, in patients who exercise to a submaximal level 
because of the effect of drugs, perfusion imaging still affords 
higher sen:;itivity than the exercise ECG alone (49). Pharma- 
cologic perfusion imaging using dipyridamole or adenosine 
appears tc be less affected by antianginal drugs and thus 
provides an appropriate alternative to exercise (IOO). 
MyocanW perjusion imaging in selected patient subsets (fe- 
n&e, elderly or obese putielirs). The treadmill ECG test is less 
accurate far diagnosis in women, who have a generally lower 
pretest likelihood than men. Myocardial perfusion imaging 
could be a logical addition to treadmill testing in this circum- 
stance. Ho&ever, the sensitivity of thallium perfusion scans 
may be low:r in women than in men (60,101). Artifacts due to 
breast atter uation, usually manifest in the anterior wall, can be 
an important caveat in the interpretation of women’s scans, 
especially when thallium-201 is used as a tracer. Theoretically, 
Tc-99m sesl.amibi may be preferable to thallium-201 scintigra- 
phy in women with large breasts .nd those with breast im- 
plants, although conclusive data on this issue are lacking. 
Positron emission tomography may also be superior in women 
with large IJreasts or breast implants, although this has not 
been studied carefully either. 
Although many elderly patients can perform an adequate 
exercise test, many are unable to do so because of physical 
impairment. Pharmaco;Jgic stress imaging is an appropriate 
option in wch patients. Very obese patients constitute a special 
problem because most imaging tables used for SPECT have 
weight-bearing limits (often 5~300 lb 1135 kg]) that preclude 
imaging very heavy subjects. These subjects can still be imaged 
by planar scintigraphy. Obese patients often have suboptimal 
perfusion images, especially with thallium-201, owing to the 
marked photon attenuation by soft tissue. In these patients, 
Tc-99m sestamibi is probably most appropriate and should 
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yield images of better qt;ality than thallium-201. Poaitron 
emission tomographic imaging is also likely to be superior in 
these subjects. 
Bundle branch bixks. Several studies have observed an 
increased prevalence of myocardial perfusion defects during 
exercise imaging, in the absence of angiographic coronary 
disease, in patients with left bundle branch block (102-104). 
These dtfects &ten involve the interventricular septum, may 
be reversible or fixed and are often absent during pharmaco- 
logic stress. Thus, perft+on imaging with pharmacologic vaso- 
dilation appears to be ulore accurate for identifying coronary 
artery disease in patients with left bundle branch block (105- 
107). Right bundle branch block or left anterior hemiblock are 
not ordinarily associated with such perfusion defects. 
Rayes’ +kwem applied to cardiac imaging. According to 
Bayes’ theorem, t‘he diagnostic value of perfusion imaging is 
,qreatest in patients with a moderate pretest likelihood (in the 
rang&O% to 60%) of having clinical coronary artery disease. 
Axong symptomatic patients, this may include middle-aged 
women with angina, patients with abnormal ECG findings at 
baseline and those with angina with atypical features. In 
patients with a very low pretest likelihood for coronary artery 
disease, positive perfusion scan results are often false positive, 
whereas with a very high pretest likelihood, negative scan 
results are often false negative. Thus, exercise myocardial 
perfusion should generally not be used for routine diagnostic 
purposes Is patients with a very low or very high likelihood of 
disease. A caveat to these Bayes’ theorem considerations is 
that negative stress scan results in a patient with coronary 
artery disease may still be prognostically important because it 
predicts a low risk for future cardiac events. Likewise, in 
patients with a high pretest likelihood for coronary artery 
disease, myocardial perfusion imaging affords useful informa- 
tion regarding the extent; severity and reversibility of myocar- 
dial hypoperfusion, which also have powerful prognostic value. 
Pharmacologic myocardial perfusion imaging. Since the in- 
troduction of dipyridamole-induced coronary vasodilation as 
an adjunct to thallium-201 myocardial perfusing imaging (108- 
110), pharmacologic interventions have become an important 
tool in the noninvasive diagnosis of coronary artery disease. 
Three drugs are commonly used as substitutes for exercise 
stress testing: dipyridamole, adenosine and dobutamine. Di- 
pyridamole and adenosine are specifically approved by the 
FDA for use in combination with myocardial perfusion scin- 
tigraphy. 
Dipyridamole causes coronary vasodilation indirectly by 
inhibiting cellular uptake of adenosine? thereby increasing the 
blood and tissue levels of adenosine, which is a potent, direct 
coronary vasodilator and markedly increases the coronary 
blood flow. The flow increase with adenosine or dipyridamole 
is of lesser magnitude through stenotic arteries, creating 
heterogeneous myocardial perfusion, which can be observed 
with a perfusion tracer. Although this mechanism can exist 
independently of myocardial ischemia, in some patients true 
myocardial ischemia can occur with either dipyridamole or 
adenosine because of a coronary steal phenomenon. The 
technical aspects of pharmacologic perfusion imaging have 
been reviewed elsewhere (100,109-123). 
Dipyridamole planar scintigraphy has a high sensitivity 
(90% average) and acceptable specificity (70% average) for 
detection of coronary artery disease (111). In studies compar- 
ing exercise and dipyridamole thallium-201 scintigraphy in the 
same patients, a similar sensitivity and tpecificity were found 
(111). Dipyridamole SPECT imaging with thallium-201 or 
Tc-99m sestamibi appears to be at least as accurate as planar 
imaging (124-126). 
Intravenous adenosine combined with thallium-201 SPECT 
has provided high sensitivity (85% average) and specificity 
(90% average) for detection of coronary artery disease 
(100,112-l 16). Results of myocardial perfusion imaging during 
adenosine infusion are similar to those obtained with dipyrid- 
amole and exercise imaging (113-115,117). Both dipyridamole 
and adenosine are safe and well tolerated despite frequent 
mild side effects, which occur in 50% (111) and 80% (118) of 
patients, respectively. Severe side effects are rare, but both 
dipyridamole and adenosine may cause severe bronchospaslr 
in patients with asthma or chronic obstructive lung disease; 
therefore, they should be used with extreme caution if at all in 
these patients. Dipyridamole and adenosine side effects are 
antagonized by theophylline, although this drug is ordinarily 
not needed after adenosine, because of the latter’s ultrashort 
half-life (<lo s). No large studies have compared adenosine 
and dipyridamole in the same patients. 
Dobutamine in high doses (20 to 40 &kg per min) 
increases the three main determinants of myocardial oxygen 
demand, namely? heart rate, systolic blood pressure and myo- 
cardial contractility, thereby eliciting a secondary increase in 
myocardial blood flow. The flow increase (two- to three-fold 
above baseline values) is less than that which is elicited by 
adenosine or dipyridamole but is sufficient to demonstrate 
heterogeneous perfusion by radionuclide imaging. Although 
the reported experience with doblrtamine perfusion imaging is 
relatively recent, the overall sensitivity and specificity are in the 
same range as those with exercise, dipyridamole or adenosine 
tests (119-122). Although side effects are frequent during 
dobutamine infusion, the test appears to be relatively safe 
(119-122). 
Radionuclide angiogruphy. Exercisr radionuclide angiogra- 
phy (either supine or upright) can be used to assess indirectly 
the presence of myocardial ischemia by demonstrating deteri- 
oration of wall motion or an abnormal left ventricular ejection 
fraction response to exercise, or both. However, this technique 
is limited by 1) acquisition of images in only one view during 
exercise (an anterior or shallow right anterior oblique view for 
first-pass studies or the “best septal” view, which aliows 
visualization of only the interventricular septum and inferoapi- 
cal and posterolateral walls); 2) degradation of images due to 
chest motion; and 3) the well known dependence of the 
“normal” left ventricular ejection fraction response on exercise 
intensity, drug effects, age and gender. Despite these limita- 
tions, the exercise left ventricular ejection fraction remains a 
powerful prognostic indicator (127,128). The ability to assess 
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both ventricular function and myocardial perfusion by Tc-95m 
sestamibi imaging constitutes a definite advantage of this 
agent, in that it allows a more comprehensive evaluation (129). 
Detection of coronnry artery disease in asymptomatic patients. 
Because of th: low positive predictive value of noninvasive 
testing in asymptomatic patients, radionuclide techniques are 
not ordinarily recommended as a screening strategy for coro- 
nary artery disease. However, a stress radionuclide test (either 
perfusion imaging or radionuclide angiography) is valuable in 
asymptomatic patients with positive exercise ECG stress test 
results, in that it may assist in determining the need for 
coronary angiography. Their use may also be justifiable in 
asymptomatic patients with known coronary artery disease to 
determine the presence and severity of inducible myocardial 
ischemia. Furthermore, in patients with documented coronary 
artery disease, SPECT myocardial perfusion imaging shows a 
similar frequency and extent of perfusion defects and revers- 
ible hypoperfusion in patients with or without chest pain 
during exercise testing (130,131). Because perfusion defects 
during exercise are strongly associated with a worse prognosis, 
the presence, extent, severity and reversibility of pel;usion 
defects often influence therapeutic decisions in patients with 
coronary artery disease with or without symptoms. 
Radionuclide imaging before noncardiac surger)? It is well 
known that patients undergoing noncardiac vascular proce- 
dures often have associated coronary artery disease that may 
or may not be clinically apparent. In these patients the peri- 
operative mortality and morbidity are usually due to underly- 
ing coronary artery disease. Hence, there is a need to thor- 
oughly assess the cardiac risk status in these patients. 
Dipyridamole thallium-201 scintigraphy has been exten- 
sively used in the preoperative cardiac evaluation of patients 
under:going noncardiac vascular procedures. Patients with nor- 
mal thallium-201 scan results or those without reversible 
defects have a very low risk of developing perioperative cardiac 
even& Conversely, those with reversible perfusion defects 
have an iacreased risk of developing cardiac complications. 
However, because the positive predictive value of an abnormal 
dipyrildamole thallium-201 scan is only between 15% and 30%, 
other clinical variables (such as the presence of a previous 
myocardial infarction and a history of diabetes mellitus, angina 
or congestive heart failure) need to be combined with the 
results of the perfusion scan to optimize risk stratification in 
these patients (132). Adenosine thallium-201 scintigraphy has 
recently been shown lo be similarly useful in the preoperative 
risk stratification of patients undergoing vascular, orthopedic 
or general surgery (133). 
Although only limited data are available (132) with respect 
to use of dipyridamole thallium-201 scintigraphy for risk 
stratification before major nonvascular procedures, dipyrida- 
mole scintigraphy may be useful in selected patients with 
documented or suspected coronary artery disease who are 
thought to be at high cardiac risk for other major operations. 
Such testing is not necessary in most patients undergoing 
nonvascular surgery because their cardiac risk is low (134). 
Evaluation of the patient undergoing noncardiac surgery will 
be the subject of a future detailed report by the ACCiAHA 
Task Force on Diagnostic iand Therapeutic Procedures. 
Diagnostic accuracy in assessment of myocardial viability 
in chrounic oronary artery disease. In a large subset of patients 
with coronary artery disease and left ventricular dysfunction, 
left ventricular performance is reduced on the basis of region- 
ally ischemir. or hibernating or stunned myocardium rather 
than irrever:;ihly infarcted myocardium (135). The detection of 
reversibly dysfunctional myocardium is clinically relevant be- 
cause regional and global left ventricular function in such 
patients will improve after revascularization. 
The requirements for cellular viability include intact sar- 
colemmal function to maintain electrochemical gradients 
across the cell membrane, as well as preserved metabolic 
activity to generate high energy phosphates. These processes 
require adequate myoca:dial blood flow to deliver substrates 
and to wash out metaboiites. Nuclear cardiology methods are 
ideally suited for this assessment. Thallium-201 SPECT and 
perfusion and metabolic PET imaging in particular ;lave 
emerged as useful methods for demonstrating viable myocar- 
dium in patients with compromised left ventricular function. 
Approaches using radionuclide angiography, including imag- 
ing immediately after exercise or nitroglycerin, have been 
reported but have not achieved wide acceptance (136-138). 
Thallium-201. The retention of thallium-201 is an active 
process that is a function of cell viability and cell membrane 
integrity. Although initial thallium uptake reflects regional 
perfusion, the ability of the myocardium to retain thallium or 
extract additional thallium over the subsequent 3 to 4 h, or 
both, is a marker of myocardial viability. Thus, a thallium 
defect on an immediate post-stress study that redistributes at 3 
to 4 h represents ischefnic but viable myasardium. However, 
many regions of severely ischemic or hibernating myocardium 
appear to have irrever-{ible thallium defects on standard or 
conventional exercise-redistribution imaging protocols. It has 
been shown that up tcl 50% of regions with “irreversible” 
thallium defects will improve after revascularization (139). 
However, such irrevemble defects are usually mi!d, with no 
more than a 25% to 5~0% reduction in thallium activity. The 
quantitative severity of the defect itself is thus one index of 
viability (139). Howeve:r, exercise-redistribution thallium scin- 
tigraphy, analyzed qualitatively, may not provide satisfactory 
precision in differentiating between infarcted and viable myo- 
cardium. 
An alternative approach uses other imaging protocols. 
Many apparently irreversible thallium defects at 3 to 4 h 
manifest substantial redistribution on late (24 to 72 h) redis- 
tribution imaging; in fact, perfusion improves after revascular- 
ization in >90% of Myocardial regions with this finding (140). 
Despite this excellent positive predictive accuracy, the negative 
predictive accuracy is less optimal because nearly 40% of 
defects that do not show early or late redistribution also 
improve after revascularization (140). These results have been 
improved substantially by the development of thallium reinjec- 
tion protocols. Up to 50% of apparently irreversible thallium 
defects on redistribution images show uptake when thallium is 
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reinjected at rest. The two published series using this method 
(141,142) invohing a total of only 45 patients, reported 
excellent positive (80% and 87%, respectively) and negative 
(82% and lOO%, respectively) predictive accuracies for im- 
provement in regional ventricular function after revasculariza- 
tion. Recent data (also involving small numbers of patients) 
(143,144) indicate that a rest-redistribution protocol in which 
thallium is injected at rest with immediate and 3 to 4-h 
redistribution imaging, with quantitative analysis of regional 
thallium activity, IS another effective means for assessing 
viability, as determined by preserved metabolic activity by PET 
and improved wall motion after revascu!arization. 
Technetium-99m sestumibi. Technetium-99m sestamibi, 
like thallium-201, requires intact cell membrane processes for 
retention and has been shown to be an excellent marker of 
cellular viability when perfusion is adequate (145). However, 
unlike thallium-201, Tc-9%m sestamibi does not redistribute 
appreciably after its initial uptake. Thus, sestamibi may have 
inherent disadvantages compared with thallium for assess- 
ment of viability in clinical situations in which blood flow is 
severely impaired (and sestamibi delivery is reduced). This 
concept is supported by three recent studies (146-148) sug- 
gesting that rest-exercise sestamibi imaging underestimates 
viable myocardium in patients with chronic coronary artery 
disease and left ventricular dysfunction compared with exercise- 
redistribution-reinjection thallium imaging or PET metabolic 
imaging. However, more recent studies (149,150) indicate that 
sestamibi may provide useful information about viability, and 
more information is needed in this area before definitive conclu- 
sions tan be reached. 
Positron emission tomographic imaging. Four PET methods 
have shown promise in providing accurate information regard- 
ing myocardial viability. The method that has achieved the 
greatest attention, and the one with the greatest patient 
validation, is the identification of intact metabolic activity in 
regions of severely underperfused and dysfunctional myocar- 
dium. For this purpose, F-18 lluorodeoxyglucose has been used 
as a marker of regional exogenous glucose utilization in such 
hypoperfused regions (151). A pattern of enhanced F-18 
fluorodeoxyglucose uptake in regions with reduced perfusion 
(termed the F-18 fluorodeoxyglucoselblood flow “mismatch”) 
indicates ischemic or hibernating myocardium that has prefer- 
entially shifted its metabolic substrate toward glucose rather 
than fatty acids or lactate. The criteia to defne F-18 Ruoro- 
deoxyglucose/blood flow mismatch have not been standard 
bed. Tne finding of preserved metabolic activity in myocardial 
regions with reduced blood flow has been shown in several 
studies (151-154) involving a total of >lOO patients, to be an 
accurate clinical marker with which to distinguish viable myo- 
cardium from myocardial fibrosis, with positive and negative 
predictive accuracies in the range of 85% in identifying regions 
that will manifest improved function after revascularization. 
Some of these studies (151,153) also suggest that the extent of 
myocardial mismatch may predict the magnitude of improve- 
ment in left ventricular function after revascularization, Fi- 
nally, the pattern of F-18 fluorodeoxyglucose/blood flow mis- 
match may have prognostic importance in patients with left 
ventricular dysfunction because patients with extensive mis- 
match have a high mortality rate during medical therapy but an 
excellent outcome after myocardial revascularization proce- 
dures (154,155). Although these studies suggest a poor out- 
come in patients with F-18 fluorodeoxyglucoseiblood flow 
misma:ch who do not undergo revascularization, these studies 
are limited by small patient numbers (total of 87 patients), 
retrospective analysis and lack of randomization. 
Alternative approaches that have been proposed for viabil- 
ity assessment with PET include assessment of oxidative 
metabolism in dysmnctional segments using C-I1 acetate 
(156), estimation of the extent of transmural perfussbk tissue 
within a dysfunctional segment using O-15 water (157) and 
analysis of the washout kinetics of rubidium-82 within a 
dysfunctional segment (158). Each of these methods has thus 
far been studied in only small numbers of patients and awaits 
confirmation in larger series. F-18 fluorodeoxyglucose, C-11 
acetate and O-15 water have not yet been approved by the 
FDA for clinical use. These three agents also require a nearby 
cyclotron for their production, which is likely to increase the 
cost of performing studies of viability. 
Positron emission tomographic versus thallium imaging. In 
keeping with the finding that as many as 50% of irreversible 
thallium defects on standard exercise-redistribution imaging 
will improve after revascularization (139), a similar percent of 
apparently irreversible defects have been shown to be meta- 
bolically active by PET (159,160). The improved accuracy of 
reinjection protocols in predicting recovery of function after 
revascularization (141,142) is paralleled by a high degree of 
concordance between thallittm reinjection imaging with PET 
imaging when both techniques are studi&in the same patients 
(161,162). In a recent series, the results of rest-redistribution 
thallium imaging also approached those of PET imaging (144). 
Finally, as noted previously, the severity of thallium defects 
also provides important information regarding viability. Even 
in defects that remain irreversible on exercise-redistribution, 
exercise-reinjection or rest-redistribution protocols, measure- 
ment of the level of thallium activity within the redistribution 
or reinjection defect (relative to normal territories) corresponds 
very well to F-18 fluorodeoxyglucose activity (144,161,163). 
Although thallium uptake provides important information 
about viability, all SPECT protocols share the limiting feaiurc 
of increased photon attenuation of a lower energy radioiso- 
:;:;;c, in which apparently irreversible thallium defects suggest- 
ing fibrosis could be attenuation artifacts in viable tissue. This 
is likely to be of greatest concern in patients with severe left 
ventricular dysfunction and dilated ventricular chambers. In 
contrast, correction for photon attenuation is a routine proce- 
dure in PET imaging. Thus, it is anticipated that imaging with 
thallium or with technetium-99m-based agents will not 
achieve the accuracy of PET imaging for assessment of viability 
until methods to correct for photon attenua!ion are perfected 
for SPECT imaging. 
In summary, positron emission tomographic imaging with a 
perfusion agent and F-18 fluorodeovglucose provides a reli- 
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able approach for identification of viable myocardium and is 
considered effective and acceptable. However, a number of 
thallium imaging protocols appear to approach the accuracy of 
metabolic PET techniques, and thallium imaging can be per- 
formed at lower cost. Thus, PET might be used to assess 
myocardial viability after a thallium test fails ‘9 provide 
detinitive evidence of viability or nonviability or if a PET study 
with a perfusion agent and F-18 fluorodeo~glucose can he 
performed at a cost equivalent to or ;ess than a SPECT study. 
It is recognized that greater experience involving larger patient 
groups is necessary to assess the relative efficacies of these two 
modalities. The use of technetium-based perfusion agents for 
SPECT imaging for myocardial viability assessment, as well 
as the use of PET imaging with C-11 acetate, O-15 water or 
rubidium-82, is considered investigational at the present time. 
Assessment of disease severity/risk stratifwation/progwsis 
in chronic coronary artery disease. Radionuclide techniques 
can be applied to the planning and monitoring of medical and 
intenentional therapies, prognostication and advice about 
activity levels and occupation in patients with documented 
coronary artery disease. 
Rudionuclide angiography. One index of coronary artery 
c&ease severity is left ventricular function. Rest left ventricular 
jection fraction is one of the most important determinants of 
long-term prognosis in patients with chronic stable coronary 
artery disease (164,165). Mortality rates increase progressively 
as left ventricular ejection fraction decreases (165). Knowledge 
of the rest LVEF is useful for determining appropriate medical 
therapies and for tiecision making about some surgical inter- 
ventions. Recommendations about reasonable levels of activ- 
ity, rehabilitation and work status also are influenced by 
knowing the degree of ventricular function impairment. 
In patients with chronic coronary artery disease, radionu- 
elide angiography can be helpful in evaluating dyspnea by 
establishing right and left ventricular performance. In those 
patients with ciinica! congestive heart failure, knowledge of left 
ventricular ejection fraction can distinguish that subset with 
systolic dysfunction. The decision to institute angiotensin- 
converting enzyme inhibitor therapy in asymptomatic patients 
with chronic coronary artery disease depends on documenting 
a reduced left ventricular ejection fraction (166). 
Left ventricular function during exercise also reflects dis- 
ease severity and provides prognostic information, In patients 
with coronary artery disease, a decline in left ventricular 
ejection fraction during exercise compared with its rest value is 
an important indicator of coronary artery disease severity and 
is associated with a poorer 3-year survival than if left ventric- 
ular ejection fraction increases during exercise (167). However, 
the absolute value of left ventricular ejection fraction at the 
peak of exercise appears to be an even stronger correlate of 
survival over the subsequent 2 to 5 years (168,169). In patients 
with mild symptoms, rest left ventricular dysfunction and one-, 
two- or three-vessel coronary artery disease, an abnormal peak 
exercise left ventricular ejection fraction or a decrease in left 
ventricular ejection fraction during exercise identify patients 
with a poorer prognosis (169-171). Hence, inducible myocar- 
dial ischemia sufficient to reduce ejection fraction during 
exercise when it is superimposed on previous myocardiai 
damage is important in determining prognosis. Patients with 
preserved left ventricular function at rest, but with enough 
inducible ischemia to severely reduce left ventricular ejection 
fraction during exercise, also appear to be at greater risk of 
death (172). However, the event rates in those with a normal 
rest LVEF are low, and one study indicates that exercise data 
do not confer independent prognostic information in such 
patients (173). 
Myocarditilperfusion imaging The number, size and loca- 
tion of &normalities on stress myocardiai perfusion studies 
reflect the location and extent of functionally significant coro- 
nary stenoses. Lung uptake of thallium-201 on postexercise or 
pharmacologic stress images is a marker of stress-induced 
global left ventricular dysfunction and multivessel coronary 
disease (174,175). Transient post-stress ischemic left ventricu- 
lar dilation also correlates with multivessel disease (176). 
These studies have suggested that SPECT may be more 
accurate than planar imaging for determining the size of 
defects, detecting coronary and left circumflex coronary artery 
disease and localizing abnormalities to the distribution of 
individual coronary arteries (177-179). 
The number, size and location of perfusion abnormalities; 
amount of lung uptake of thallium-201 on post-stress images; 
and presence or absence of transient post-stress ischemic left 
ventricular dilatation can be used together to facilitate identi- 
fication of important patient subsets. such as those with 
multivessel disease, left main coronary artery disease and 
disease of the proximal segment of the left anterior descending 
coronary artery. A most important objective is the detection of 
left main or multivessel coronary artery disease because pa- 
tients with surgical intervention have improved survival com- 
pared those receiving medical therapy. Almost all patients with 
left main or multivessel coronary disease have abncirmal 
thallium scan results (lSO-184). 4 left main pattern, charac- 
terized by reduced thallium uptake in the septum and anterior 
and lateral wails is uncommon; rather, -60% of patients have 
multiple thallium defects, and almost 50% have abnormal lung 
uptake of thallium. Using planar thallium imaging, quantita- 
tive analysis of perfusion defects and thallium washout, con- 
sideration of lung uptake of thallium and other clinical and 
ECG indicators of high risk disease, -86% of patients with left 
main coronary artery disease will have one or more of these 
high risk indicators (180). Within a specific coronary distribu- 
tion, the size and severity of a perfusion defect is related 
generally to the site and severity of a coronary stenosis. Larger 
and more severe defects correlate with proximal and more 
severe stenoses (185-188). 
Stress perfusion imaging may be performed to assess 
changes in the magnitude of ischemic myocardium. The pres- 
ence and extent of altered perfusion may be similar regardless 
of the presence or absence of symptoms (131,132). There are 
no data documenting the value of serial testing in asymptom- 
atic patients or patients with chronic stable angina. However, 
sequential testing, generally no more frequently than yearly, 
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may be useful in some patients. Such studies are also fre- 
quently performed after angiography to better assess the 
functional significance of an anatomic stenosis (189,190). In 
patients with symptomatic angina, worsening of symptoms or a 
change in symptom character may provoke concern about 
disease progression. Stress perfusion scintigraphy, especially 
when compared with previous studies, can provide an objective 
basis for the change in symptoms and guide subsequent 
therapies. 
Prediction of important cardiac events can be inferred from 
the results of stress myocardial perfusion imaging. The most 
consistent predictor of cardiac death or nonfatal myocardial 
infarction appears to be the number of transient perfusion 
defects, whether provoked by exercise or pharmacologic stress 
(191-198). The number of coronary vessels with angiographic 
disease may be less indicative of subsequent prognosis while 
providing important supplemental information (191,199). The 
size of the perfusion abnormality was the single most impor- 
tant prognosticator in a StJdy establishing independent and 
incremental prognostic information from SPECT thallium-201 
scintigraphy over that obtained from clinical, exercise treadmill 
and catheterization data (200). Three studies (174,175,201) 
have shown that increased lung uptake of thallium induced by 
exercise or pharmacologic stress is associated with an increased 
risk of cardiac events. Increased lung uptake is related to 
multivessel coronary artery disease and stress-induced eleva- 
tion of left ventricular filling pressures and, as such, is an 
indirect index of jeopardized myocardium that reflects exten- 
sive myocardial infarction or ischemia, or both. 
Normal post-stress thallium scan results are highly predic- 
tive of a benign prognosis, even in patients with known 
coronary disease (191-208). A collation of 16 studies involving 
3,594 patients followed up for a mean of 29 months revealed 
that the rate per year of cardiac death or myocardial infarction 
was 0.9% (209) nearly as low as that of the general population 
(210). 
Combined assessment of function and perfusion. A combi- 
nation of perfusion and functional information during stress 
and at rest may be helpful in categorizing disease extent and 
severity (211-213). This combined information can be pro- 
vided by performance of two separate exercise tests (e.g., stress 
perfusion scintigraphy and stress radionuclide angiography) or 
by combining the studies after a single exercise test (e.g., 
first-pass radionuclide angiography with technetium-99m- 
based agents followed by perfusion imaging). However, the 
incremental benefit of the added information provided by 
combined perfusion and ventricular function exercise testing 
has not been demonstrated in clinical outcome or prognostic 
studies, and in general a single measurement of rest left 
ventricular function and a measure of exercise/pharmacologic 
stress-induced perfusion or exercise ventricular function, but 
not both, are appropriate. 
Radionuciide imaging before and after revascularization 
interventions. Myocardial perfusion imaging is a useful ad- 
junct in the planning of revascularization procedures by virtue 
of its ability to demonstrate whether a given coronary stenosis 
is or is not associated with a stress-induced perfusion abnor- 
mality (214-216). Although less critical in coronary bypass 
graft surgery, where typically all suitable vessels with significant 
angiographic stenoses (~50%) are bypassed, perfusion imag- 
ing is particularly useful in determining the functional impact 
of single or multiple stenoses before percutaneous translumi- 
nal coronary angioplasty. This is especially important when 
coronary angioplasty is targeted to the “culprit lesion,” that is, 
the ischernia-provoking stenosis. Similarly, because restenosis 
is a frequent problem after successful coronary angioplasty, 
stress SPECT perfusion imaging is particularly well suited for 
the functional evaluation of patients after coronary angioplasty 
and as a means of assessing the occurrence of restenosis. The 
ideal time for patients to undergo imaging after coronary 
angioplasty is controversial, but -4 weeks after coronary 
angioplasty appears to be a good time to assess the functional 
results of angioplasty (217-220). Perfusion imaging in these 
patients may be pet-formed in conjunction with exercise or 
pharmacologic vasodilation (221-223). 
Exercise radionuclide angiography is also useful in selected 
patients for assessing the results of coronary angioplasty 
(224,225). Rest left ventricular ejection fraction does not 
usually improve after successful angioplasty but may improve 
in those patients with ventricular dysfunction caused by acute 
ischemia or more chronic hibernation. In the presence of 
widespread ischemia before angioplasty, exercise left ventric- 
ular ejection fraction would be expected to decrease and should 
improve after angioplasty. Regional wall motion at peak exercise 
would also be exnected to improve after angioplasty and may be 
a more specific indicator of successful angioplasty than improve- 
ment in left ventricular ejection fraction. 
When coronary angioplasty has been performed largely for 
symptom relief, follow-up testing is not generally recom- 
mended unless symptoms recur. In the absence of symptoms, 
the task force does not endorse routine testing, given the lack 
of data that outcomes are affected by this approach. 
Miocardial perfusion scintigraphy can be useful in several 
situations after coronary bypass surgery. Patients with ST-T 
wave abnormalities at rest can be better evaluated for recur- 
rent myocardial ischemia by scintigraphy than by ECG tread- 
mill testing. In addition, -30% of patients have an abnormal 
ECG response on treadmill testing (226) early after bypass 
surgery, and these patients can be assessed for possible incom- 
plete revascularization and extent of myocardium affected. 
Patients with initial negative postoperative treadmill test re- 
sults that later become positive usually have progressive isch- 
emia due either to graft closure or progression of disease in the 
native circulation (227). Myocardial perfusion scintigraphy can 
be useful in determining the location, extent and severity of 
such ischemia. 
With knowledge of anatomy before bypass surgery and the 
territories that have been bypassed, the scintigraphic data can 
help to determine whether the ischemia is m?st likely caused 
by patho!ogic results of bypass graft surgery, incomplete revas- 
cularization or new disease (228,229). However, in general 
radionuclide testing should be performed after bypass surgery 
JACC Vol. 25, No. 2 ACCIAHA TASK FORCE 535 
February 1995521-47 GUIDELINES FOR CLINICAL CARDIAC RADIONUCLIDE IMAGING 
Table 4. Uses of Radionuclide Testing in Diagnosis of Chronic Ischemic Heart Disease 
Indication Test Class 
I. Diagnosis of symptomatic and selected patients with 
asymptomatic myocardial ischemia 
2. Assessment of ventricular performance (rest or 
exercise) 
3. Assessment of myocardial viability in patients with 
left ventricular dysfunction in planning 
revascularization 
4. Planning PTCA-identifying lesisns causing 
myocardial ischemia. if not othetwisc known 
5. Risk stratification before noncardiac ~urgety 
6. Screening of asymptomatic patients with low 
likelihood of disease 
Exercise or pharmacologic myorardial 
perfusion imaging, including PET* 
Exetcisc RN.4 
RNA? 
Gated sestamihi imaging 
Rest-redistribution ‘Tl-201 imaging 
Stress-redistribution-reinjection Tl-201 
imaging 





Exercise or pharmacologic myocardial 
perfusion imaging 
Exercise RNA 

















*The relative cost of positron emission computed tomography (PET), thallium (TI)-201 or technetium (Tc)-99m 
agents and lesser availability of PET must be considered when selecting this technique. tRest radionuclidc angiographv 
(RNA) can be aceomp!ished by first-pass imaging of a technetium-based myocardial perfusion agent. F-18 = fluorine-18: 
NTG = nitroglycerin; other abbreviations as in Table 1. 
only if symptoms recur, except as noted earlier. Tables 4 to 4 
summarize radionuclide testing in chronic coronary artery 
disease. 
Myocarditis 
Dii,gnosis. The diagnosis of myocarditis generally can be 
established on the basis of a careful history, physical examina- 
tion and ECG and chest X-ray studies. Endomyocardial biopsy 
is useful in selected patients to confirm the diagnosis. The 
presence of myocardial inflammation can be assessed using 
radiotracers that are taken up by involved myocardium (Table 
7). Both gallium-67 citrate (230) and Tc-99m pyrophosphate 
have been used for this purpose, but both false positive and 
false negative results are common. Pyrophosphate would be 
used to detect myocardial necrosis in this setting. More 
recently, indium-11 l-labeled antimyosin antibody imaging has 
been found to have a high specificity for making this diagnosis, 
Table 5. Uses of Radionuclide Testing in Assessment of Severity/ 
Prognosis/Risk Stratification of Chronic Ischemic Heart Disease 
Indication 
1. Assessment of LV performance 
Test Class 
Rest or exercise RNA 1 
Gated sestamibi perfusion IIb 
imaging 
2. Identification of extent and severity of Exercise or pharmacologic I 
ischcmia and localization of ischemia myocardial perfusion 
imaging 
Abbreviations as in Tables 1 and 2. 
although with a limited sensitivity (231); this agent remains 
investigational at the present time. 
In patients with suspected myocarditis, radionuclide angiog- 
raphy often provides useful information by detecting left and 
right ventricular dysfunction. Although ventricular dysfunction 
in acute myocarditis is generally diffuse and results in gener- 
alized hypokinesia, isolated left or right ventricular dysfunction 
may exist, and regional wall motion abnormalities may occur. 
With thallium imaging, fixed focal defects are occasionally 
found in patients with active myocarditis, but there is usually 
homogenous dirtiibution of thallium. 
Assersment of disease severity/risk stratification/prognosis. 
Because the three prognostic factors-ventricular dysfunction, 
ventricular arrhythmias and exercise tolerance-are interre- 
lated, severe ventricular dysfunction, as measured by radionu- 
elide angiography, is a marker of patients with a poorer 
prognosis who may require a limited work and activity pre- 
scription. 
Assessment of therapy. The utility of serial gallium or 
Tc-99m pyrophosphate scans in the management of patients 
with myocarditis has not been established; however, in some 
cases clinical improvement with immunosuppressive therapy 
has correlated with a resolution of gallium uptake by the 
myocardium. Indium-111 antimyosin antibody imaging might 
be useful for assessing the response of the left ventricle to 
immunosuppressive therapy, but this application requires fur- 
ther confirmation. Because the morbidity and mortality of 
myocarditis are largely related to the extent of ventricular 
dysfunction, radionuclide angiographic determinations of right 
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Table 6, Uses of Xadionuclide Testing in Assessment of Interventions in Chronic Ischemic 
Heart Disease 
Indication Test CktSS 
1. Assessment of drug therapy 
a. Ventricular performance 
b. Myocardial perfusion 
2. Assessment for restenosis after PTCA 
(ymptomatic) 
Rest or exercise RNA 
Erefcise perfusion imaging 
Exercise or pharmacologic perfusion imaging 
Exercise RNA 
3. Assessment of ischemia in symptomatic Exercise or pharmacologic perfusion imaging 
patients after CABG Exercise RNA 
4. Assessment of selected asymptomatic patients 
after PTCA or CABG, such as patients with 
an abnormal ECG response to exercise or 
those with rest ECG changes precluding 
identification of ischemia during exercise 
5. Routine assessment of asymptomatic patients 
afrer PTCA or CABG 
Exercise or pharmacologic perfusion imaging 
Exercise RNA 
All tests 111 
CABG = coronary artery byoass graft surgery; PTCA = percutaneous transluminal coronary angioplasty; other 
abbreviations as in Tables 1 and 3. 
arid left ventricular size and performance are valuable for 
assessing the effects of management in such patients. Myocar- 
dial perfusion imaging is of little value in this regard. Radio- 
nuclide testing in myocarditis is summarized in Table 7. 
Dilated Cardiomyopathies 
Diagnosis. Determination of ventricular ci7” and function 
using radionuclide angiogtaphy is a useful tec’inique in estab- 
lishing the diagnosis of dilated cardiomyopathy (232,233). 
Although global biveniricular dysfunction is common, left 
ventricular dysfunction is usually more advanced. Thallium 
imaging most often reveals left ventricular dilation and homog- 
enous or diffusely inhomogeneous uptake. Large defects (i.e., 
40% of the circumference-of the left ventricler strongly favo; 
left ventricular dysfunction due to ischemic heart disease, and 
a reversible defect usually indicates ischemia rather than scar. 
However, large, fixed (particularly apical) defects have been 
reported in patients with dilated cardion+pathy. Metabolic 
imaging with positron emission tomography may be helpful in 
making this distinction (234). 
Gallium-67 citrate and technetium-99m pyrophosphate im- 
aging have been used to detect active myocarditis in patients 
with apparent dilated cardiomyopathy, but positive scans also 
occur in patients with various forms of infiltrative or degener- 
ative heart disease. Greater specificity may be achieved using 
Table 7. Uses of Radionuclide Imaging in Myocarditis and Cardiom;+athies 
Indication 
I. Demonstration of myocardial inflammation and 
response to therapy 
2. Determination of initial and serial LV and RV 
performance in myocdrditis or dilated, hypertrophic 
and restrictive cardiomyopathy 
3. Initial and serial evaluation of LV function in 
patients receivirg chemotherapy with doxorubicin 
4. Differentiation of ischemic and dilated 
cardiomyopathy 
5. Establishment of diagnosis of hypertrophic 
cardiomyopathy 
6. Diagnosis of concomitant coronary artery disease 
in hypertrophic cardiomyopathy 
7. Assessment of myocardial iscbemia in hypertrophic 
cardiomyopathy 
8. Cardiac involvement in systemic diseases 
Test 









Rest ‘IS201 imaging 
TI-201 or Tc-99m sestamibi imaging 
TI-201 imaging 
RNA 
















Abbreviations as in Tables I, 2 ar J 4. 
Myocardial imaging with ‘II-201 Ilb 
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indium-111 antimyosin antibodies, but scans may be negative evaluation of exercise ejection fraction does not appear to be 
in patients with “myocarditis” on endomyocardial biopsy (see helpful in determining when to discontinue doxorubicin ther- 
preceding section on myocarditis). apy (236). 
Risk stratification and prognosis. Determination of ven- 
tricular performafice by radionuclide angiography provides an 
excellent means of assessing prognosis and activity guidelines 
in patients with dilated cardiomyopathy. Exercise radionuclide 
angiography is of no proven value. GaUium-67 citrate, Tc-99m 
pyrophosphate and thallium imaging are of little value for risk 
stratification. 
Assessment of therapy. Assessment of ventricular perfor- 
mance by radionuclide angiography is useful for guiding the 
management of patients with dilated cardiomyopathy. Radio- 
nuclide testing in cardiomyopathies is summarized in Table 7. 
In addition to the slow, indolent reduction in ventricular 
performance that is measurable during serial administration of 
doxorubicin, doxorubicin also commonly produces immediate 
deterioration in ventricular function with a single administra- 
tion that is rapidly reversible over the course of several days. 
Because of the possibility of such immediate changes in 
ventricular function, radionuclide angiographic studies to fol- 
low the long-term progression of cardiotoxicity should be 
timed at least 10 to 14 days after the last dose of doxorubicin. 
The use of radionuclide testing during doxorubicin therapy is 
summarized in Table 7. 
Doxorubicin Cardiotoxicity Hypertrophic Cardiomyoputhy 
Diagnosis. Chemotherapy with doxorubicin produces a dose- 
dependent impairment of lefi ventricular function because of 
toxic effects on cardiac myocytes. The dilated cardiomyopathy 
that results from doxorubicia usually produces severe, irrevers- 
ible left ventricular dysfunction before the onset of symptoms 
of congestive heart failure. Ventricular dysfunction is progres- 
sive if doxorubicin therapy is continued after objective evi- 
dence of reduced systolic function (235). Radionuclide angiog- 
raphy is ideally suited as a noninvasive tool to provide 
quantitative measures of left ventricular dysfunction in pa- 
tients who have received or are continuing to receive doxoru- 
bicin therapy (235-237). 
Diagnosis. The diagnosis of hypertrophic cardiomyopathy 
can generally be established on the basis of the clinical 
examination and ECG and echocardiographic studies. Radio- 
nuclide studies are usually not indicated but may be of value in 
selected patients. Radionuclide angiography frequently dem- 
onstrates hyperdynamic left ventricular systolic function and 
dib,-*oportion& upper septai thickening in patients with hy- 
peerophic cardiomyopathy (238,239). In addition, impaired 
left ventricular diastolic filling can be detected in the majority 
of patients (239). 
Risk stratification and prognosis. Left ventricular dysfunc- 
tion, as measured by reduced ejection fraction and serial 
reduction in ejection fraction, is an important determinant of 
prognosis in patients who have received or are currently 
receiving doxorubicin. In addition, patients with left ventricu- 
lar dysfunction from preexisting cardiac conditions are at 
greater risk of congestive heart failure if doxorubicin therapy is 
to be initiated. In such patients, measurement of ejection 
fraction before beginning doxorubicin treatment is valuable 
and may determine whether doxorubicin should be adminis- 
tered or whether alternative chemotherapeutic strategies 
should be entertained. 
Asymmetric septal hypertrophy may also be detected by 
thallium imaging by comparing septal thickness with that of the 
posterior left ventricular free wall (240). Typically, thallium 
images demonstrate a small left ventricular cavity with marked 
thailium uptake by the hypertrophied myocardium. The detec- 
tion of concomitant coronary artery disease by thallium imag- 
ing is not possible in the presence of hypertrophic cardiomy- 
opathy because reversible, exercise-induced thallium def.ecF 
occur commonly in patients with hypertrophic cardiomyopathj 
in the absence of epicardial coronary artery stenoses (241). 
Assessment of therapy. Serial evaluation of left ventricular 
ejection fraction at rest by radionuclide angiography has been 
shown to be an effective means of following up patients during 
the course of doxorubicin therapy. Data from several studies 
indicate that it is safe to continue doxorubicin therapy if rest 
ejection fraction remains ahave the lower limit of normal, even 
if serial studiLls indicate a consistent decline in ejection fraction 
compared with baseline values. If doxorubicin therapy is 
discontinued when ejection fraction becomes subnormal, ven- 
tricular function usually stabilizes at that point without the 
development of clinically overt heart failure in tile future 
(235-237). In contrast, further doxorubicin administration 
once rest ejection fraction decreases below normal runs the 
risk of precipitous impairment in ventricular function associ- 
ated with serious, life-threatening heart failure (235). Serial 
Risk stratification/prognosis. There an no definitive data 
to recommend radionuclide imaging techniques for risk strat- 
ification. However, the demonstration of depressed left ven- 
tricular systolic function identifies a patient subgroup with a 
relatively poor prognosis. In addition, recent data (242) sug- 
gest that young patients with hypertrophic cardiomyopathy 
who have reversible perfusion defects on exercise thallium 
imaging may also be at high risk. 
Assessment of therapy. The demonstration of normal or 
supranormal left ventricular systolic function despite symp- 
toms of congestive heart failure is useful in determining that 
therapy with beta-blockers or calcium channel blockers is 
appropriate. Serial assessment of left ventricular function or 
myocardial perfusion may be helpful in selected patients who 
develop progressive symptoms during the course of medical 
therapy by identifying those patients who have developed 
myocardial scarring and depressed left ventricular systolic 
function in the course of the natural history of their disease. 
Such patients usually manifest irreversible thallium defects 
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Table 8. Uses of Radionuelide Imaging in Congenital Heart Disease in Adults 
Indication Test Class 
1. Detection and localization of skmts 
2. Quantitation of left-to-right shunting 
3. Initial and serial assessment of 
ventricular function 
4. Diagnosis of ar ,Gzs of coronary 
circulation 
First-pass RNA for left-to-right shunts 
Lung perfusion scanning for right-to-left shunts 
First-pass RNA 
Carbon-15 oxygen inhalation 
RNA 







Abbreviations as in Table 1. 
(241). Thallium imaging may also be useful in assessing the 
effects of therapy in reducing myocardiai ischemia (243), 
although there arc limited data supporting this approach. 
Radionuclide testing in hypertrophic cardiomyopathy is sum- 
marized in Table 7. 
Restrictive Cardiomyopathies 
Diagnosis. A variety of diagnostic procedures, including 
cardiac catheterization, are usually necessary to establish the 
diagnosis. Characteristically, radionuclide angiography demon- 
strates normal or decreased left ventriclllar end-diastolic vol- 
ume, narmal or mildly depressed left ventricular ejection 
fraction and dilated atria. Myocardial uptake of Tc-99m pyro- 
phosphate or gallium, or both, is common but can be due to 
various conditions, including amyloidosis, sarcoidosis, progres- 
sive systemic sclerosis and cardiac tumors. Fixed defects in 
myocardial thallium-201 images often occur in patients with 
sarcoidosis, progressive systemic sclerosis or cardiac tumors 
(244,245). 
Resultant time-activity curves derived from different chambers 
can be used to distinguish an intracardiac from an extracardiac 
(patent ductus arteriosus) shunt. Right-to-left shunts can be 
detected from inspection of the tracer bolus as it traverses the 
heart, with early visualization of either the left heart chambers 
or the aorta. Left-to-right shunts can be quantitated using the 
pulmonary/systemic fiow ratio from the time-activity curve 
over the right lung. Quantitation also appears possible using 
C-15 oxygen inhalation with positron emission tomography. 
Radionuclide angiography provides useful information 
about the influence of the shunt on left and right ventricular 
performance. Lung perfusion scanning using intravenous in- 
jection of macroaggregates of albumin may be used for iden- 
tifying right-to-left shunting. Appearance of technetium activ- 
ity in brain and splanchnic viscera suggests right-to-left 
shunting. Rest and exercise thallium-201 imagmg can define 
abnormal perfusion patterns in patients with anomaious coro- 
nary arteries or other types of congenital heart disease in which 
coronary blood flow may be regionally diminished. 
Risk stratification/prognosis. There are no current data to 
support th: use of radionuclide imaging techniques for this 
purpose. 
Risk stratification/prognosis. The usefulness of radionu- 
elide imaging, including rest and exercise studies, for decision 
making related to limitation of activity and work status remains 
to be defined. 
Assessment of therapy. Under special circumstances, serial 
measurements of ventricular performance by radionuclide 
angiography ma$ be meful to follow the course of patients with 
those disorders and t..) document the effects of specific therapy 
(i.e., therapy for hi;?,ochromatosis). The uses of radionuclide 
testing in myocarditis and cardiomyopathies are summarized in 
Table 7. 
Congenitcl Heart Disease in thp Adult 
Diagnosis. Echocardiography, properly applied, is the im- 
aging method of choice for evaluating patients with known or 
suspected congenital heart disease because this modality is 
useful in identifying structural abnormalities and intracardiac 
shunting. However, in selected patients there are potentially 
important applications of nuclear cardiology techniques 
(Table 8). 
Assessment of therapy. Serial assessmerit of shunt flow by 
first-pass radionuclide angiography may reveal spontaneous 
closure, successful surgical closure or residual ieft-to-right 
shunting. Relative lung perfusion also can be quantitared by 
measurement of count data over the right and left lung fie!ds. 
Patency of palliative shunts can be demonstrated by careful 
assessment of pulmonary dilution curves or by pulmonary 
perfusion imaging. Evaluation of left and right ventricular 
ejection fractions by radionuclide angiography may be useful in 
determining the optimal time for surgical correction in patients 
with left or right ventricular pressure or volume overload states 
and in relating any postoperative symptoms to residual ven- 
tricular dysfunction. The uses of radionuclide testing in con- 
genital heart disease are summarized in Table 8. 
Hypertensive Heart Disease 
In left-to-right shunting, first-pass radionuclide angiography Diagnosis. Radionuclide angiography at rest is useful for 
demonstrates persistent high levels of activity in the lungs or the accurate assessment of left ventricular systolic function in 
right ventricle, or both, as a result of early recirculation (246). patients with hypertension (class I). Assessment of left ventric- 
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ular peak diastolic filling rates by radionuclide angiography 
(247,248) may identify impaired diastolic function when sys- 
tolic function is normal (class Ila). 
Exercise radionuclide angiography is unreliable in identify- 
ing patients with coexistent coronary artery disease because an 
abnormal ejection fraction response to exercise occurs com- 
monly in patients with hypertension (249). However, the 
abnormal exercise response occurs chiefly in patients with left 
ventricular hypertrophy (248,250); most patients without hy- 
pertrophy manifest normal ventricular function with exercise. 
In patients without left ventricular hypertrophy, stress 
myocardial perfusion imaging can be useful for detecting 
reversible defects among those who have coexistent ischemic 
heart disease (class I). Perfusion imaging appears to be more 
reliable than radionuclide angiography in identifying coexist- 
ent coronary artery disease in patients with left ventricular 
hypertrophy. 
Risk stratification/prognosis. Determination of left ven- 
tricular performance by radionuclide angiography may influ- 
ence decisions concerning work status and ex;ent of activity 
(class IIb). 
Assessment of therapy. Radionuclide angiography is use- 
ful for evaluating the effect of blood pressure reduction and 
other medical therapy on left ventricular systolic function in 
patients with hypertension who have left ventricular dysfunc- 
tion (class I). 
Posttransplant Cardiac Disease 
The major clinical problems of heart transplant recipients 
that can be evaluated with radionuclide testing relate to early 
postoperative left and right ventricular performance, rejection 
and coronary arteriopathy. Ventricular dysfunction in the 
perioperative period and allagraft rejection account for most 
deaths (251). Coronary arteriopathy is a major cause of 
morbidity and mortality in the late phase after heart transplan- 
tation (252). 
Anatomic differences of the transplanted heart are impor- 
tant with respect to both radionuclide angiography and perfu- 
sion imaging. The donor hear& manifests increased cardiac 
mobility, paradoxic septal motion and leftward rotation with 
posterior displacement of the apex. As a result, the optimal left 
anterior oblique acquisition position is ~50” in >60% of 
patients (253). The quality of planar thallium-201 images can 
be affected by this rotation such that the ventricular cavity may 
appear small or nonexistent. Thus, SPECT imaging may offer 
advantages over planar acquisition of both radionuclide an- 
giography and perfusion scintigaphy by minimizing the effects 
of abnormal rotation and attenuation from overlapping struc- 
tures. 
Diagnosis and monitoring UC transplant rejection. Radio- 
nuclide angiography. Abnormal ieft or right ventricular func- 
tion, or both, during the first few days after transplantation is 
most likely not due to rejection, but beyond the first week 
depressed left ventricular function in the dbsence of another 
clinical etiology will most likely be secondary to rejection. Mild 
episodes are accompanied by myocardial inflammaticn that 
resolves with treatment, whereas mar; severe episodes result 
in myocardial necrosis. Although definitive diagnosis depends 
on myocardial biopsy results, several radionuclide techniques 
may be helpful for detecting and tracking rejection. Radionu- 
elide angiocardiography has been the most studied technique. 
Although some patients with rejection may have marked left 
ventricular dysfunction, the majority with mild rejection and 
some with moderate or severe rejection have normal left 
ventricular function (253). Serial evaluation may be necessary 
for detecting rejection because the changes are often subtle: 
One study (254) showed that left ventricular ejection fraction 
decreased from 63% to 57% in patients whose biopsy results 
changed from no to moderate rejection and from 63% to 59% 
in those whose biopsy findings changed from no to mild 
rejection (254). Ejection fraction improved in successfuiiy 
treated patients whose biopsy findings showed histologic reso- 
lution. 
Reproducibility of radionuclide angiographic measure- 
ments may be enhanced by denervation and hence more 
regular heart rates. To detect the small changes that may occur 
during rejection, meticulous attention to technique is essential, 
including precise reproduction of the same acquisition angles 
from study to study. With severe rejection and reduced left 
ventricular ejection fraction, sequential radionuclide angiogra- 
phy can be helpful in monitoring therapy. 
Other radionuclide imaging techniques for diagnosis and 
management of rejection. Iridium-1 11 labeled lymphocyte im- 
aging has been shown in animal models to detect rejection 
before overt myocardial necrosis occurs. However, in ~rmtans 
the degree of lymphocyte infiltration is variable and may not be 
severe in cyclosporine-treated patients despite significant re- 
jection (255). Furthermore, uptake of labeled lymphocytes is 
not specific for rejection and also occurs with toxoplasmosis 
and cytomegalovirus myocarditis. 
Antimyosin antibody uptake correlated with biopsy findings 
of rejection in 80% of scans in one study (256). The intensity 
of its uptake correlates with histopathologic rejection score. A 
persistent increased heart/lung ratio during the first year after 
transplantation is associated with rejection-related comphca- 
tions, and a decreasing ratio correlates with a favorable clinical 
outcome. Beyond the first year after transplantation, elevated 
heartflung ratios of antimyosin correlate with a higher number 
of rejection episodes and a greater probability of developing 
rejectio? (255257-259). Antimyosin antibody remains investi- 
gational at the present time. Gallium-67 imaging is useful for 
detecting acute and chronic inflammatory lesions in the body, 
but its prelimiiary application in transplant rejection has been 
disappointing (260). 
Radionuclide techniques in diagnosis and management of 
allograft vasculopathy. Posttransplant arteriopathy is a 
unique, diffuse process preferentially involving the mid and 
distal coronary vessels and causing branch vessel pruning and 
occlusions. Because the heart is denervated, chest pain does 
not occur, and presentation with sudden cardiac death, myo- 
cardial infarction, congestive heart failure and arrhythmias is 
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Table 9. Uses of Radionuclide Testing After Cardiac Transolantation 
Indication 
1. Assessment of ventricular performance 
2. Detection and monitoriog of ejection 
3. Assessment of coronary arteriopathy 
a. Detection 




Exercise or pharmacologic myocardial 
perfusion imaging 








Abbreviations as in Table 1. 
more likely. Detection of disease is important because percu- 
taneous transluminal coronary angioplasty, coronary bypass 
and retransplantation are therapeutic options for some pa- 
tients found to have transplant coronary arteriopathy. 
There is insufficient information to evaluate perfusion 
imaging for the routine assessment of transplant recipients. 
The available data (261,262) in small numbers of patients, 
suggest that planar and SPECT thallium-201 after oral dipyr- 
idamole are poorly sensitive and specific for coronary artery 
disease. A more recent study (263) using exercise stress and 
SPECT thallium-201 or sestamibi reported a sensitivity of 77% 
and specificity of 100%. There are no specific data about the 
usefulness of radionuclide techniques in prognosis, rehabilita- 
tion and risk stratification or after intervention in transplant 
recipients. Table 9 summarizes the uses of radionuclide testing 
in transplant recipients. 
Valvular Heart Disease 
Diagnosis. The major use of radionuchde angiography in 
regurgitant lesions is to reliably and seri.dly evaluate left ?nd 
right ventricu!ar ejection fraction. AL, left and right ventric- 
ular volume can be estimated by radioactive count-based 
methods using equilibrium techniques (264,265). Ventricutai 
enlargement suggests that regurgitation is at least moderate in 
severity. In addition, larger end-systolic and end-dias:oh; 
volumes impk a worse prognosis (266). Radionuclide imdping 
is not useful in diagnosing aortic valve regurgitation secmdary 
to aortic dissection. 
Both first-pass and equilibrium radionuchde angiography 
have been used to assess the severity of aortic or mitral 
regurgitarion, or both. The difference in stroke counts between 
the right 2nd left ventricles provides an index of the extent of 
volume overload in the absence of tricuspid regurgitation. The 
regurgitation fraction in a patient with left ventricular volume 
overload can be approximated using the stroke counts of the 
left ventricle minus the stroke counts of the right ventricle 
divided by the stroke count of the left ventricle (267,268). 
Difficulty in separating the counts from enlarged ventricles and 
atria and the frequent occurrence of multivalvular regurgita 
tion limit the accuracy of this method. 
Assessment of disease severity/risk stratificatiodprognosis. 
Myocardial perfusion imaging provides little information con- 
cerning risk stratification of valvular heart disease, Radionu- 
elide angiographic assessment of right and left ventricular 
ejection fractions and volumes is useful in making decisions 
concerning prognosis, posttreatment rehabilitation and work 
status, whereas the value of radionuclide angiography with 
exercise continues to be investigated. 
Assessment of interventions. Decisions about the timing of 
valve repair or replacement for aortic or mitral regurgitation or 
aortic stenosis are often based on assessing the effect of the 
valve lesion or lesions on ventricular performance at rest. 
Thus, radionuclide angiography is very useful for determining 
ventricular ejection fractions in the initial and serial evaluation 
of symptomatic and asymptomatic patients with severe valvular 
stenosis or regurgitation, or both, and in assessing the effects 
of valve replacement or repair on left ventricular function 
(269-273). In addition, assessment of right ventricular function 
is clinically useful in patients with chronic mitral regurgitation 
(270). The significance of a reduction, rather than an increase, 
in left ventricular ejection fraction during exercise in patients 
with aortic or mitral regurgitation remains controversial 
(272,273). 
There arc few indications for thallium imaging in patients 
with valvula; heart disease, although it is sometimes used to 
diagnose and assess concomitant coronary artery disease. 
Exercise perfusion imaging in patients with valvular heart 
disease may be helpful in certain situations. Negative results in 
p:;lients with mitral valve prolapse or in those with other forms 
of valvutat heart disease generally indicate the absence of 
Ll,,lI ziy lisease. However, specificity is reduced in patients 
v.,th mitral valve prolapse or left ventricular hypertrophy. In 
pa ients who are candidates for valvular surgery, coronary 
arteriigraphy remains the most appropriate method for the 
-tef; Xve diagnosis of concomitant coronary artery disease. In 
pa,.< xs with known coronary artery disease, especially those 
with te&ms of borderline significance (50% to 70% diameter 
stenosis), stress perfusion imaging may be useful in evaluating 
the significance of symptoms and in planning medical or 
surgical therapy. In patients who have been treated surgically 
for valvular heart disease and who have undergone concomi- 
tant coronary artery bypass graft surgery, myocardial perfusion 
imaging can be performed to assess postoperative ischemia, as 
described previously in the section on evaluation of bypass 
surgery. 
Exercise radionuclide angiography is also of little value in 
detecting coronary disease in patients with valve disease be- 
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Table 10. Uses of Radionuclide Testing in Valvnlar Heart Disease 
Indication Test ChSS 
1. Initial and serial assessment of LV and RV volume 
and ejection fraction 
2. Quantitation of aortic or mitral regurgitation 
3. Detection and assessment of functional significance 
of concomitant coronary artery disease 
4. Detection of aortic dissection and its complications 













cause of the nonspecific nature of regional wall motion abnor- 
malities at rest or during exercise. Rest radionuclide angiog- 
raphy is of some value in assessing the results of medical 
therapy on the severity of aortic or mitral regurgitation (274). 
Also, the changes in left and right ventricular ejection fractions 
and volume after valve repair or replacement can be evaluated 
accurately by rddionuclide angiography. 
Risk stratification for rehabilitation, occupation and prog 
nosis. Myocardial perfusion imaging provides little informa- 
tion concerning risk stratification of valvular heart disease. 
Radionuclide angiograpbit assessment of right and left ven- 
tricular ejection fractions and volumes is useful in making 
decisions concerning prognosis, posttreatment rehabilitation 
and work status, whereas the value of radionuclide angiogra- 
phy with exercise continues to be investigated. Table 10 
summarizes the uses of radionuclide testing in patients with 
valvular heart disease. 
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